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Previous literature for stereocomplementary enzymatic cyclopropanation and 
enantioselective, intermolecular unactivated alkene cyclopropanation 
 
Supplemental Table 1a. Literature precedent for stereocomplementary cyclopropanation of 
styrenyl alkenes via carbene transfer. Reference numbers are given for the main text reference 
numbers. 
 
 Trans-cyclopropane Cis-cyclopropane 
 (R,R) (S,S) (R,S) (S,R) 
Ref 11, 
10.1126/science.1231434 
Not reported 
Up to 98% de, 
96% e.e. 
Up to 84% de, 
97% e.e. 
Not reported 
Ref 13, 
doi/10.1002/cbic.201600528 
Up to 86% de, 
32% e.e. 
Up to 98% de, 
97% e.e. 
Up to 78% de, 
99% e.e. 
Up to 42% de, 
95% e.e. 
Ref 17, 
10.1002/anie.201608680 
Up to 99.9% de, 
95% e.e. 
Up to 99.9% 
de, 99.9% e.e. 
Not reported Not reported 
Ref 34, 
10.1021/jacs.7b00768 
Up to 99.5% de, 
92% e.e. 
Up to 99.9% 
de, 99.9% e.e. 
Not reported Not reported 
 
 
Supplemental Table 1b. Current state-of-the-art methods for the enantioselective, intermolecular 
cyclopropanation of unactivated alkenes. Because iron-catalyzed asymmetric examples are not 
known, achiral examples are listed for iron. 
  
Entry Metal 
Catalyst 
Ref. Note 
1 Fe 1 Iron porphyrin-catalyzed, achiral. Two examples involved 
unactivated alkenes. 
 
Fe(PFP)Cl (0.02-0.05 mol%) catalyzed the cyclopropanation of 2-
ethyl-1-butene (100 eq.) with EDA in 390 TON, d.r. not reported. 
 
PFP = meso-tetrakis(pentafluoropheny1)porphyrin 
 
2 Fe 2 Iron porphyrin-catalyzed, achiral. One example involved 
unactivated alkenes. 
 
Fe(TPP)Cl (3 mol%) catalyzed the cyclopropanation of allyl 
benzene with in situ generated trifluoromethyl diazomethane (1.5 
eq.) in water with 3.3 TON, d.r. not reported. 
 
TPP = 5,10,15,20-tetraphenyl-21H,23H-porphine 
 
3 Fe 3 Iron porphyrin-catalyzed, achiral. One example involved 
unactivated alkenes.  
 
This example is similar to entry 2, but a different in situ method was 
used to generate the trifluoromethyl diazomethane. No product was 
detected.  
 
4 Fe 4 Iron porphyrin-catalyzed, achiral. Three examples involved 
unactivated alkenes.  
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Fe(TPP)Cl (10 mol%) catalyzed the cyclopropanation of aliphatic 
alkenes using in situ generated difluoromethylcarbene (2 eq.) in 6-8 
TONs, 7:1 to 13: 1 d.r. (trans). 
 
5 Rh 5-13 All Rh-carboxylate or Rh-carboxamidate-catalyzed (0.2-2 mol% Rh) 
examples of unactivated alkene cyclopropanation reported are 
trans-selective.  
 
The most efficient and selective examples are the cyclopropanation 
of 1-hexene (72 TTN, >20:1 d.r. (trans), 96% e.e.), and 1-octene 
(70 TTN, >20:1 d.r. (trans), 90 % e.e.). 
 
7 Ir 14 Ir-salen (1 mol%) catalyzed the cyclopropanation of >10 
unactivated alkenes with up to 93 TTN, 98:2 d.r. (cis major), 99% 
e.e.. 
  
8 Ir 15 Ir(Me)PPIX in engineered myoglobin (0.5 mol%) catalyzed the 
cyclopropanation of 1-octene in 40 TON, 91:9 er, 40:1 d.r. (trans 
major). 6 equivalents of EDA were added via syringe pump over 12 
h. 
 
9 Ir 16 Ir(Me)PPIX in engineered CYP119 enzymes catalyzed the 
cyclopropanation of a variety of unactivated alkenes (terminal, 
internal and 1,1-disubstituted) with up to 1300 TON and 99% e.e.. 3 
equivalents of EDA were added via syringe pump over 3 h. 
 
10 Ru 17, 18 Ru-(iminophosphoranyl)ferrocene (2 mol%) catalyzed the 
cyclopropanation of 3 unactivated alkenes with up to 37 TON, 
72:28 d.r. (cis major), 98% e.e.. 
 
11 Co 19, 20 All Co-catalyzed (1-5 mol% Co) examples of unactivated alkene 
cyclopropanation reported are cis-selective and based on Co-
porphyrins. 
 
The most efficient and selective example is the cyclopropanation of 
phenylbutene (90 TTN, >99:1 d.r. (cis), 96% e.e.). 
 
12 Cu 21, 22 All Cu-catalyzed (1 mol% Cu) examples of unactivated alkene 
cyclopropanation reported are trans-selective. 
 
The most efficient and selective example is the cyclopropanation of 
1-octene (80 TTN, 93:7 d.r. (trans), 90% e.e.). 
 
 
Safety statement 
No unexpected or unusually high safety hazards were encountered in these methods. While ethyl 
diazoester (EDA) has well-defined usage and risks, use of more volatile and reactive diazo 
compounds (e.g. diazoalkanes) should be performed with caution (for example procedures, see 
reference 23).  
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Nomenclature for compound labeling 
Alkenyl substrates are named 2x (where x is a-m). The corresponding cyclopropyl esters (from 
reaction with ethyl diazoacetate 1) are named 3x. Single diastereomer compounds are named 
cis-3x or trans-3x. The 1-octene cyclopropane products, whose absolute configuration is known 
(see Compound chiral separation conditions and representative traces), are labeled (1(R/S), 
2(R/S))-3a. Alkenyl substrates with functional groups protected (e.g. 7-octen-1-ol, 7-octen-1-oic 
acid) are named 2xa, and their corresponding cyclopropane products are named 3xa. These are 
depicted in Supplemental Figure 1. 
 
Supplemental Figure 1. Compound nomenclature used in this work. 
 
Materials and Methods 
Solvents and reagents were ordered from Sigma Aldrich, TCI, CombiBlocks, or Alfa Aesar and 
used without further purification. GC-FID data were collected on a Shimadzu GC-17A, Agilent 
6850 GC system, and Agilent 7820A GC system. GC-MS data were collected on a Shimadzu 
GCMS-QP2010 SE. Screening HLPC-UV data were taken on an Agilent 1200 series HPLC. 
Normal-phase chiral HPLC data were taken on an Agilent 1100 series HPLC. NMR spectra were 
recorded on a Bruker Prodigy 400 MHz instrument or Varian 300 MHz instrument with CDCl3 as 
solvent. 1H NMR spectra were recorded at 400 MHz and 13C NMR spectra were recorded at 100 
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MHz. Chemical shifts were normalized to the chloroform solvent’s protio impurity (1H NMR 7.26 
ppm, 13C NMR 77.16 ppm). Optical rotation data were collected on a JASCO P-2000 Polarimeter.  
 
Proteins tested in enzyme discovery 
Genes encoding eleven heme-binding proteins were ordered as codon-optimized gBlocks 
(Integrated DNA Technologies, Coralville, Iowa) and assembled into pET22b(+) with the pelB 
leader sequence removed and a C-terminal 6xHis tag. As the putative distal ligand could interfere 
with the initially low substrate binding affinities, the proteins were ordered with the distal axial 
ligands mutated to smaller, nonpolar residues, found to be beneficial for vinylarene 
cyclopropanation in myoglobin24. Some gBlocks (Supplemental Table 2) were also ordered with 
a mutation in a putative entrance tunnel residue previously found to enhance styrene 
cyclopropanation activity in myoglobin.24 These heme proteins were first tested for 
cyclopropanation activity using 1,7-octadiene and EDA as substrates (1,7-octadiene was chosen 
for its higher effective concentration of terminal olefin). The most active and selective proteins 
identified from these experiments, protoglobin from Aeropyrum pernix (ApePgb) and nitric oxide 
dioxygenase from Rhodothermus marinus (RmaNOD), were subsequently tested as wild-type 
proteins against 1-octene 2a, a commonly used model substrate for unactivated alkene 
cyclopropanation studies.  
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Supplemental Table 2. Heme-binding proteins tested for unactivated alkene cyclopropanation 
activity using 1,7-octadiene and EDA as substrates. 
UniProt ID Organism Annotation 
Mutation(s) 
from WT 
Cyclopropane 
product formation 
detected 
Q3IDI7 
Pseudoalteromonas 
haloplanktis 
Putative hemoglobin-like 
oxygen-binding protein 
Y42V F69A No 
Q7CX73 Agrobacterium fabrum Uncharacterized protein Y26V F53A No 
Q5L1S0 Geobacillus kaustophilus 
Hypothetical conserved 
protein 
Y29V Q50A No 
Q9NPG2 Homo sapiens Neuroglobin 
F28V F61I 
H64A 
No 
Q0PB48 Campylobacter jejuni Truncated hemoglobin none No 
B3DVC3 
Methylacidiphilum 
infernorum 
Hemoglobin IV H71V L93A Yes 
D0MGT2 Rhodothermus marinus Nitric oxide dioxygenase Y32V Q52A Yes 
G7VHJ7 Pyrobaculum ferrireducens Protoglobin Y58V Yes 
Q9YFF4 Aeropyrum pernix Protoglobin Y60V Yes 
O66586 Aquifex aeolicus Thermoglobin Y29V Q50A Yes 
 
 
 
Screening previously engineered cytochromes P411  
 
A composite plate of 36 P411-CIS proteins from lineages engineered for non-natural reactions 
such as aziridination, sulfimidation, amination, and non-styrenyl, activated alkene 
cyclopropanation25 was screened for activity and selectivity in 3a product formation. Most 
reactions showed trace activity and moderate diastereoselectivity, but the highest activities by a 
large margin were found in the lineage engineered for N-vinyl amide cyclopropanation (O. F. 
Brandenberg et al., unpublished results). Screening this lineage for stereoselectivity showed that 
P411-CIS L437F T438Q L75Y L181I, referred to in this study as P411-UA, had the highest activity 
and enantioselectivity. It was therefore used as a starting point in unactivated alkene 
cyclopropanation. 
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Homology models 
ApePgb was modeled with the Methanosarcina acetivorans protoglobin (PDB ID: 3ZJL) and 
RmaNOD was modeled with Alcaligenes eutrophus flavohemoglobin (PDB ID: 1CQX) using 
SWISS-MODEL.26 A homology model of P411-UA was generated through side-chain mutations 
to the P411-CIS crystal structure (PDB ID: 4H23). Figures generated from protein homology 
models and crystal structures were made with PyMOL (Schrödinger, Inc.).  
 
Subcloning and transformation of genes 
Genes for Aeropyrum pernix protoglobin (ApePgb) and Rhodothermus marinus nitric oxide 
dioxygenase (RmaNOD) were ordered as codon-optimized gBlocks (Integrated DNA 
Technologies, Coralville, Iowa). The gBlocks were amplified via polymerase chain reaction (PCR) 
and the PCR products were gel extracted and purified with Zymoclean Gel DNA Recovery Kit 
(Zymo Research Corp, Irvine, CA). The PCR product was subcloned into pET22b(+) via Gibson 
assembly.27 Gibson assembly products were transformed into electrocompetent E. cloni 
EXPRESS BL21(DE3) cells (Lucigen, Middleton, WI) with a Gene Pulser Xcell (Bio-Rad, 
Hercules, CA). Aliquots of SOC medium (750 µL) were added and the cells were incubated at 
37°C and 230 rpm for 45 minutes before being plated on LB-ampicillin (100 µg mL1) agar plates. 
Overnight cultures (5 mL LB-amp in culture tubes) were grown at 37°C and 230 rpm for 12-18 
hours. Overnight cultures were used to inoculate flask cultures, prepare glycerol stocks, and 
isolate plasmids. Plasmids were isolated with Qiagen Miniprep kits and the genes were sequence 
verified (T7 promoter / terminator sequencing primers, Laragen, Inc.).  
 
Protein expression 
Cultures of Hyperbroth (HB, AthenaES) with 100 µg mL1 ampicillin in unbaffled Erlenmeyer flasks 
were inoculated 1% (v/v) with stationary-phase overnight cultures and shaken in an Innova 42 
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shaker at 230 rpm, 37°C. At OD600 = 0.8, cultures were chilled on ice for 20 minutes. Protein 
expression was induced with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and heme 
production was enhanced with supplementation of 1 mM 5-aminolevulinic acid (ALA). The 
cultures were shaken at 180 rpm and 22°C overnight (18-24 hours). Cells were pelleted via 
centrifugation at 4000 g for 10 minutes at 4°C. The supernatant was decanted and the cells were 
resuspended in M9-N buffer supplemented with 25 mM glucose.  
 
Site-saturation library construction 
Site-saturation mutagenesis was performed using the 22-codon method.28 Briefly, 
oligonucleotides were ordered with NDT, VHG, and TGG codons in the coding strand at the amino 
acid position to be saturated. A reverse primer complementary to all three forward primers was 
also ordered. Two PCRs were performed for each library, the first containing a mixture of forward 
primers (12:9:1 NDT:VHG:TGG) and a pET22b(+) internal reverse primer and the second 
containing the complementary reverse primer and a pET22b(+) internal forward primer. The two 
PCR products were gel-purified with Zymoclean Gel DNA Recovery Kit (Zymo Research Corp, 
Irvine, CA) and ligated together via Gibson assembly. The Gibson assembly product was 
transformed into electrocompetent E. cloni EXPRESS BL21(DE3) cells (Lucigen, Middleton, WI). 
Aliquots of SOC medium (750 μL) were added and the cells were incubated at 37°C for 45 minutes 
before being plated on LB-ampicillin (100 µg mL1) agar plates. 
 
Site-saturation library expression 
Single colonies from the LB-ampicillin agar plates were picked using sterile toothpicks and grown 
in 300 µL LB-ampicillin in 2 mL 96 deep-well plates at 37°C, 250 rpm, 80% humidity overnight 
(12-18 hours). Multi-channel pipettes were used to transfer 30 µL of starter culture into deep-well 
plates containing 1 mL HB-amp per well. Glycerol stocks of these plates were prepared in parallel 
by adding starter culture (100 µL) and 50% (v/v) sterile glycerol (100 µL) to a 96-well microplate, 
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which was then stored at 80°C. The deep-well expression culture plate was incubated at 37°C, 
250 rpm, 80% humidity for 2.5 hours. The plate was then chilled on ice for 30 minutes. The 
cultures were induced with 0.5 mM IPTG and supplemented with 1 mM ALA to increase cellular 
heme production. The plate was incubated at 22°C and 250 rpm overnight. The plate was 
centrifuged at 4000×g for 10 minutes at 4°C.  
Site-saturation library reactions and screening  
The pellets in the site-saturation library deep-well plates were resuspended in nitrogen-free M9 
minimal medium (47.7 mM Na2HPO4, 22.0 mM KH2PO4, 8.6 mM NaCl, 2.0 mM MgSO4, and 0.1 
mM CaCl2, abbreviated as M9-N, 400 µL). In an anaerobic chamber, 50 µL reactant mixture in 
ethanol (final concentrations in a 450 µL reaction: 20 mM EDA 1, 20 mM 4-phenyl-1-butene 2b) 
were added to the reaction plate. The reaction plate was covered with a pierceable foil cover (USA 
Scientific) and shaken at 500 rpm for 3 hours. To quench the reaction and extract the substrates, 
400 µL of a mixture of acetonitrile (49 mL) and 3 M HCl (1 mL) was added to each well. The 
reaction plate was shaken for an additional 30 minutes, followed by centrifugation (4000×g, 10 
minutes, 4°C). The supernatant was filtered through a 0.2 µm PTFE 96-well filter plate into a 96-
well microplate (4000×g, 1 minute, RT). The microplate was sealed with a pierceable foil cover. 
The wells were screened for activity and diastereoselectivity of 3b formation via HPLC using a 
Kromasil 100-5-C18 column, 4.6x50 mm with a 71% acetonitrile isocratic method (3 minutes). In 
later screening with higher enzymatic activity, the separation of cis- and trans-isomers of 3b was 
improved with the use of an Eclipse XDB-C18 column, 5 µm particle size, 4.6x150 mm and a 6-
minute 71% acetonitrile isocratic method. Wells with improved activity relative to the parent 
protein were streaked out from the glycerol stock onto LB-amp plates. A single colony was picked 
and grown in 5 mL LB-amp overnight (230 rpm, 37°C). These overnight cultures were used in 
flask protein expression and small-scale biocatalytic reactions to verify enhanced activity and/or 
selectivity relative to the parent sequence.  
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Sonicated lysate preparation and hemochrome assay 
An aliquot of cells for protein concentration determination was sonicated (QSonica Q500 
Sonicator, 1/8 in tip) for 2 minutes, 1 second on, 1 second off at 25% amplitude. Cells expressing 
ApePgb or RmaNOD variants had 0.1 eq. Bugbuster 10X protein extraction reagent (EMD 
Millipore) added prior to sonication. The sonicated lysate was clarified via centrifugation at 4500×g 
and 4°C for 10 minutes. The concentration of heme-loaded protein was determined with the 
pyridine hemochromagen (hemochrome) assay.29 Briefly, sonicated and clarified lysate (500 μL) 
was sterile filtered and added to a cuvette. 500 μL of solution I (0.2 M NaOH, 40% (v/v) pyridine, 
500 μM potassium ferricyanide) was added and the spectrum of this oxidized sample was taken 
from 350-600 nm. Sodium dithionite (10 μL of 0.5 M solution in 0.5 M NaOH) was added and the 
reduced spectrum was taken from 350-600 nm. The pyridine hemochromagen concentration was 
determined using its Q bands, with extinction coefficient 23.98 mM1 cm1 for (557 nmreduced – 540 
nmoxidized).30 
 
Small-scale, whole-cell biocatalytic reaction preparation and work-up 
Small-scale reactions were set up in 2 mL GC crimp vials. E. coli expressing the appropriate heme 
protein catalyst (380 µL, adjusted to the appropriate optical density or protein concentration) was 
added to the vials and they were brought into a Coy anaerobic chamber (~ 0-10 ppm O2). To each 
vial was added alkene (final concentration 10 mM) followed by EDA 1 (final concentration 20 mM) 
with 5% ethanol as a cosolvent. Directly following addition of EDA, the reaction vial was crimped 
and shaken at 500 rpm at RT. Reactions were worked up by the addition of HCl (16 µL, 3 M stock) 
and internal standard (16 µL of 40 mM acetophenone in cyclohexane). Cyclohexane (700 µL) was 
added and the reaction was transferred into 1.7 mL Eppendorf tubes for extraction. The extraction 
was carried out with a Retsch MM 301 mixing mill (1 minute, 30 Hz / 1800 rpm). Samples were 
centrifuged at 20000×g for 5 minutes at RT and the organic layer was used for chromatographic 
analysis. 
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Preparative-scale, whole-cell biocatalytic reaction setup and product purification 
Whole cells resuspended in M9-N supplemented with 25 mM glucose were brought into a Coy 
anaerobic chamber. Whole-cell catalyst was added to unbaffled Erlenmeyer flasks, followed by 
alkene (5 mM, 1.0 eq.) and EDA (10 mM, 2.0 eq.) diluted in ethanol (5% final ethanol cosolvent). 
The reactions were sealed and shaken at room temperature at 180 rpm for 16 hours. The product 
was extracted three times from the aqueous reaction mixture with 1 volume eq. of 2:1 
pentane:diethyl ether. The organic layer was dried with sodium sulfate and concentrated via rotary 
evaporation. The concentrated reaction mixture was then purified via flash chromatography 
(Biotage, Inc.). Pentane:diethyl ether gradients were generally more effective at separating the 
cyclopropane products from the EDA dimer byproducts. Fractions containing cyclopropanation 
products were pooled and concentrated in vacuo.  
 
Supplemental Table 3. Conditions for the preparative-scale reactions reported in the manuscript. 
3k and 3l were run at higher reaction volume due to the lower molecular weight of the substrates 
(and corresponding products). 
Product Protein variant used Reaction volume (mL) Whole-cell OD600 
3i ApePgb AGW 40 8 
3j ApePgb AGW 40 8 
3k RmaNOD Q52V 80 10 
3l ApePgb AGW 80 10 
3m ApePgb AGW 40 8 
 
 
Large-scale protein expression and purification 
HB-amp (1 L in 2.8 L unbaffled flask) was inoculated with 1% (v/v) overnight culture and shaken 
at 37°C, 160 rpm. At OD600 = 1.3 – 1.5 the flasks were chilled on ice for 20 minutes. Protein 
expression was then induced with 0.5 mM IPTG and 1 mM ALA and the cultures were grown for 
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24 hours at 22°C and 140 rpm. The cultures were pelleted (4000×g, 5 minutes, 4°C) and frozen 
at –20°C. The cells were resuspended in binding buffer (25 mM Tris HCl pH 7.5, 100 mM NaCl, 
25 mM imidazole). Hemin (1 mg gwet cells–1) was added to increase heme loading of the protein and 
DNase I (0.1 mg mL–1) was added to reduce lysate viscosity. The cells were sonicated, the lysate 
was clarified via centrifugation (20,000×g, 20 minutes, 4°C), and the clarified lysate was filtered 
(0.45 µm sterile filter). The protein was purified via HisTrap (1 mL column) on an ÄktaPurifier (GE 
Healthcare Life Sciences), using a 25 mM – 300 mM imidazole gradient over 10 column volumes. 
Fractions containing the protein of interest were pooled and buffer exchanged via centrifugal 
concentration to a 25 mM Tris HCl pH 7.5, 25 mM NaCl. The buffer-exchanged protein was flash-
frozen and stored in 25 µL aliquots at –80°C. The purified protein concentration was determined 
using the bicinchoninic acid assay (BCA assay, Thermo Scientific) using the standard protocol 
provided. 
 
Small-scale lysate and purified protein reactions 
Small-scale reactions were set up in 2 mL GC crimp vials. Lysate or purified protein was diluted 
to the desired concentration with M9-N buffer (no glucose added), added to the vials, and brought 
into a Coy anaerobic chamber (~ 0-10 ppm O2). To each vial was added sodium dithionite (final 
concentration 2 mM), alkene (final concentration 10 mM), and EDA 1 (final concentration 20 mM) 
with 5% ethanol as a cosolvent. Directly following addition of EDA, the reaction vial was crimped 
and shaken at 500 rpm at RT. Reactions were worked up by the addition of HCl (16 µL, 3 M stock) 
and internal standard (16 µL of 40 mM acetophenone in cyclohexane). Cyclohexane (700 µL) was 
added and the reaction was transferred into 1.7 mL Eppendorf tubes for extraction. The extraction 
was carried out with a Retsch MM 301 mixing mill (1 minute, 30 Hz / 1800 rpm). Samples were 
centrifuged at 20000×g for 5 minutes at RT and the organic layer was used for chromatographic 
analysis. 
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Determination of hemin-catalyzed cyclopropanation activity 
Hemin-catalyzed cyclopropanation reactions were set up as small-scale reactions above; hemin 
(50 µM final concentration) in M9-N buffer, with or without 1 mg mL–1 bovine serum albumin (BSA), 
was brought into the Coy anaerobic chamber in 2 mL glass crimp vials. To each vial was added 
sodium dithionite (final concentration 2 mM), alkene (final concentration 10 mM), and EDA 1 (final 
concentration 20 mM) with 5% ethanol as a cosolvent. Directly following addition of EDA, the 
reaction vial was crimped and shaken at 500 rpm at room temperature for 16 hours.  
 
 
Protein engineering strategies 
 
Rhodothermus marinus nitric oxide dioxygenase (RmaNOD): 
3b and EDA 1 were used as substrates to engineer RmaNOD for improved activity and selectivity 
in the production of (1S, 2S)-3b. The wild-type gene was mutated at active-site positions Y32 (the 
putative distal axial ligand), Q52, and V97 using single-site site-saturation mutagenesis. Though 
modest improvements in activity in the Y32X site-saturation mutagenesis library was observed, 
the most significant increase in activity from this first round was the Q52V mutation. This mutation 
also enhanced the diastereo- and enantioselectivity to near-perfect. 
 
Aeropyrum pernix protoglobin (ApePgb): 
3b and EDA 1 were used as substrates to engineer ApePgb for improved activity and selectivity 
in the production of (1R, 2S)-3b. The wild-type gene underwent site-saturation mutagenesis at 
position Y60 (the putative distal axial ligand). This yielded the Y60G variant as the most active 
catalyst. ApePgb Y60G was then subjected to single-site site-saturation mutagenesis at W59, 
F73, F93, and F145 in parallel, all of which are positions known to modulate the gaseous ligand 
binding properties of the homologous Methanosarcina acetivorans protoglobin.31 The variant that 
showed the greatest increase in activity while maintaining high selectivity was W59A Y60G. This 
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new variant was used to parent the next round of single-site site-saturation mutagenesis at 
positions F73, F93, and F145. After verification in small-scale biocatalytic reactions, ApePgb 
W59A Y60G F145W demonstrated a significantly increased in enantioselectivity for the 
production of (1R, 2S)-3b.  
 
Previously engineered Bacillus megaterium variant P411-CIS L437F T438Q L75Y L181I 
(P411-UA): 
3b and EDA 1 were used as substrates to screen P411-UA variants for improved selectivity in the 
production of (1S, 2R)-3b. The engineered P411-UA was first mutated at positions previously 
mutated in its lineage relative to P411-CIS. A simultaneous NDT double site-saturation 
mutagenesis library at F437/Q438 and single 22-codon site-saturation mutagenesis libraries28 at 
Y75 and I181 were generated and screened for improved diastereoselectivity in the formation of 
3b. In each case P411-UA was among the most active and selective variants. Using P411-UA as 
parent protein, we next performed single-site site-mutagenesis at additional active site residues 
V87, I263, E267, and A328, screening for enhanced diastereoselectivity. The most significant 
changes in diastereoselectivity were in the V87X site-saturation library, in which an enhanced cis 
diastereoselectivity mutation (V87C) and an inversion in stereochemistry (V87F, producing the 
(1R, 2R)-isomer) were found. 
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Protein homology models 
 
Supplemental Figure 2. Homology models of proteins engineered in the study. The protein and 
proximal ligand are shown in gray. Red indicates residues at which mutations were made for the 
engineered variants. The heme cofactor is shown in blue. a) ApePgb homology model with W59A, 
Y60G, and F145W mutations in red. b) RmaNOD homology model with Q52 and the putative 
distal ligand Y32 (where mutations also enhanced activity) in red. c) P411-UA homology model 
with V87C in red, as well as other mutated residues 75, 181, 437, and 438 colored. 
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Cyclopropanation activity and selectivity of whole-cell variants, purified proteins, and 
cell lysates  
 
Supplemental Table 4. Activity and selectivity of hemin controls, wild-type protein, and 
engineering lineage intermediate proteins in 3a product formation. Mean and standard deviation 
were determined from two biological replicates of technical duplicates. The reactions were 
performed on analytical scale (10 mM 2a, direct addition of 20 mM 1, 16-hour anaerobic reaction). 
n.d.: not determined. The diastereoselectivity ratio (d.r.) is given as cis:trans and the enantiomeric 
excess (e.e.) is given for the major diastereomer. 
 
Catalyst TTN d.r. e.e. (major) 
Hemin 0.39 ± 0.04 25 : 75 n.d. 
Hemin + BSA 0.41 ± 0.03 23 : 77 n.d. 
RmaNOD WT 27 ± 9 3 : 97 89% 
ApePgb WT 18 ± 2 81 : 19 69% 
ApePgb Y60G 140 ± 40 82 : 18 96% 
ApePgb W59A Y60G 360 ± 90 85 : 15 96% 
P411-UA 500 ± 130 89 : 11 94% 
 
 
 
Supplemental Table 5. Activity and selectivity of wild-type and engineering lineage intermediate 
proteins in 3b product formation. Mean and standard deviation were determined from two 
biological replicates of technical duplicates. The reactions were performed on analytical scale (10 
mM 2b, direct addition of 20 mM 1, 16-hour anaerobic reaction). The diastereoselectivity ratio 
(d.r.) is given as cis:trans and the enantiomeric excess (e.e.) is given for the major diastereomer. 
 
Protein TTN d.r. e.e. (major) 
RmaNOD WT 34 ± 4 17 : 83 71% 
ApePgb WT 85 ± 3 88 : 12 81% 
ApePgb Y60G 125 ± 3 83 : 17 94% 
ApePgb W59A Y60G 570 ± 50 80 : 20 94% 
P411-UA 2500 ± 130 91 : 9 >99% 
 
 
The four final protein variants were tested under whole-cell, aerobic conditions at analytical scale 
(400 µL) for their ability to form 3a. The reactions were set up under the same conditions as the 
anaerobic analytical-scale reactions, with the exception that they were set up outside of the Coy 
anaerobic chamber. The aerobic conditions resulted in a nearly complete loss in cyclopropanation 
for the globins, with only traces of 3a detected. The formation of EDA dimer was also severely 
attenuated, suggesting carbene formation was significantly slower under these conditions. The 
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P411-UA variants had a substantial loss in activity, but were still catalytically active (P411-UA 
V87C: 140 ± 5 TTN, 95:5 d.r.; P411-UA V87F: 25 ± 3 TTN, 6:94 d.r.). The loss of activity for the 
globins but not P411s could be due to the globins’ high affinity for gaseous ligands like O2, CO, 
and NO32, whereas some engineered P411-BM3 variants have previously been shown to function, 
albeit with attenuated catalytic activity, in aerobic conditions33. In addition to being tested as 
anaerobic and aerobic whole-cell catalysts, the final protein variants were tested as sonicated cell 
lysates and as purified proteins. In cell lysate the proteins have decreased in activity relative to 
whole-cell catalysis. The enzymes also had decreased activity as purified proteins. In both lysate 
and purified protein, the catalysts maintained their stereoselectivity. 
 
Supplemental Table 6. Activity and selectivity of final protein variants as whole-cell, sonicated 
cell lysate, and purified protein for 3a product formation. The reactions were performed on 
analytical scale (10 mM 2a, direct addition of 20 mM 1, 16-hour anaerobic reaction). Whole-cell 
catalyst loading was OD600= 5 (ApePgb AGW, RmaNOD Q52V) and OD600=20 (P411-UA V87C, 
P411-UA V87F). Cell lysates were diluted to the apparent OD600= 5 (ApePgb AGW, RmaNOD 
Q52V) and OD600=20 (P411-UA V87C, P411-UA V87F), corresponding to protein concentrations 
of 0.9 – 2.1 µM. Catalyst loading in purified protein reactions was 5 µM. The diastereoselectivity 
ratio (d.r.) is given as cis:trans. 
 
 Whole cell Cell lysate Purified protein 
Protein TTN d.r. TTN d.r. TTN d.r. 
RmaNOD Q52V 100 ± 6 < 1 : 99 43 ± 2 < 1 : 99 53 ± 9 < 1 : 99 
ApePgb AGW 490 ± 20 89 : 11 190 ± 9 89 : 11 80 ± 10 87 : 13 
P411-UA V87C 270 ± 30 95 : 5 56 ± 4 95 : 5 6.9 ± 0.9 95 : 5 
P411-UA V87F 310 ± 20 4 : 96 54 ± 5 5 : 95 13 ± 2 4 : 96 
 
 
Decreased activity in lysate and purified protein relative to whole-cell reactions has been observed 
in many enzyme-catalyzed carbene transfer reactions34,35 and is likely due to reduced carbene 
transfer-based enzyme inactivation in whole cells36. Whole cells could also be stabilizing the 
protein (through proper macromolecular crowding effects, chaperones, etc.). As our focus was on 
developing a straightforward system for biocatalysis, we opted for whole-cell catalysis that does 
not require additional catalyst purification steps. 
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Supplemental Table 7. Substrate scope and diastereoselectivity of the four final variants. 
Activities were confirmed via GC-MS. +: activity against the substrate. *: trace activity detected. 
–: no detectable activity. n.d.: not determined. Diastereoselectivity ratio is given as cis:trans. 
 
Alkene, product 
P411-UA 
V87C 
ApePgb AGW P411-UA V87F RmaNOD Q52V 
1-octene (3a) +, 95:5 d.r. +, 89:11 d.r. +, 4:96 d.r. +, <1:99 d.r. 
4-phenyl-1-butene (3b) +, 96:4 d.r. +, 84:16 d.r. +, <1:99 d.r. +, 3:97 d.r. 
benzyl acrylate (3c) +, 91:9 d.r. +, 71:29 d.r. +, 2:98 d.r. +, <1:99 d.r. 
6-bromo-1-hexene (3d) +, 92:8 d.r. +, 92:8 d.r. +, 4:96 d.r. +, <1:99 d.r. 
vinyl cyclohexane (3e) * +, 76:24 d.r. * * 
methylenecyclohexane (3f) * + + * 
1-penten-3-one (3g) * +, 89:11 d.r. * +, <1:99 d.r. 
2-vinylpyridine (3h) * * * +, <1:99 d.r. 
7-octen-1-ol (3i) + +, 91:9 d.r. * * 
7-octen-1-oic acid (3j) n.d. +, 83:17 d.r. n.d. n.d. 
(E)-penta-1,3-diene (3k) +, 96:4 d.r. +, 91:9 d.r. +, 31:69 d.r. +, 4:96 d.r. 
(Z)-penta-1,3-diene (3l) 
+, 55:45 
d.r. 
+, 93:7 d.r. +, 35:65 d.r. +, 35:65 d.r. 
5-hexen-2-one (3m) – +, 94:6 d.r. – * 
 
 
Supplemental Table 8. GC yields for analytical-scale reactions reported in Figure 2 in the 
manuscript. These yields are determined by comparing the GC yield to the calibration curves 
(Calibration curves for analytical-scale TTN determination). These reactions were run under the 
conditions given above (Small-scale, whole-cell biocatalytic reaction preparation and work-up). 
These reactions were run under conditions designed to demonstrate the catalysts’ potential TTNs, 
rather than yields (TTN and stereoselectivity information in main text Figures 2 and 3). 
 
Alkene, product P411-UA V87C ApePgb AGW P411-UA V87F RmaNOD Q52V 
1-octene (3a) 4% 8% 7% 5% 
4-phenyl-1-butene (3b) 26% 40% 44% 4% 
benzyl acrylate (3c) 40% 91% 53% 71% 
6-bromo-1-hexene (3d)  19%   
vinyl cyclohexane (3e)  18%   
methylenecyclohexane (3f)  10%   
1-penten-3-one (3g)  41%   
2-vinylpyridine (3h)    60% 
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Compound synthesis and characterization  
General procedure A: 
Rhodium acetate dimer (10 µmol, 4.4 mg) and a stir bar were added to a 5 mL dram vial and it 
was sealed with a septum. The sealed vial was purged with three cycles of vacuum and argon. 
Neat olefin (8 mmol) was added to the vial. EDA (2 mmol) was added in a 2-hour slow addition 
on ice and reacted overnight at room temperature. The crude reaction mixture was concentrated 
in vacuo and loaded on a SNAP Ultra silica flash cartridge. The reaction mix was separated on 
an Isolera flash purification system (Biotage, Charlotte, NC) with a hexane/ethyl acetate gradient. 
Fractions containing the desired product were pooled and concentrated in vacuo. Yields were 
approximately 5-30%, due in part to both significant EDA dimer formation and low conversion of 
the unactivated alkenes. 
 
General procedure B: 
Rhodium acetate dimer (40 µmol, 17 mg) and a stir bar was added to a scintillation vial and sealed 
with a septum. The sealed vial was purged with three cycles of vacuum and argon. The vial was 
charged with alkene (5 mmol) and dichloromethane (5 mL). EDA 1 (2.0 eq. diluted in 4 mL 
dichloromethane) was added at room temperature by slow addition over 2 hours and reacted 
overnight at room temperature. The crude reaction mixture was concentrated in vacuo and loaded 
on a SNAP Ultra silica flash cartridge. Using pentane/diethyl ether as eluents, the reaction mix 
was separated on an Isolera flash purification system (Biotage, Charlotte, NC). Fractions 
containing the desired product were pooled and concentrated in vacuo. Yields of pure fractions 
were approximately 5-30%, due in part to both significant EDA dimer formation and low 
conversion of the unactivated alkenes. This method is preferable for more volatile alkenes, and 
the pentane/diethyl ether gradients appeared to give better separation from the EDA dimer 
byproducts compared to the hexanes/ethyl acetate gradient. 
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Determination of absolute configurations of the cyclopropane products 
Absolute configurations of 3a were confirmed by comparison to literature chiral GC.15 Cyclosil-B 
column, 90°C isothermal, absolute configuration of products elute in order: cis (1S, 2R)–3a, (1R, 
2S)–3a, trans: (1R, 2R)–3a, (1S, 2S)–3a. The absolute configurations of other compounds in this 
study were not determined, but one could infer them by analogy, assuming the facial selectivity 
of the diazo reagents and olefins from which these products were made remains the same for 
each protein variant. The inferred absolute configurations provided here should be used with 
caution, understanding that substrate effects could have inverted the absolute stereochemistry. 
The chiral separation conditions for all cyclopropane products are detailed in the section below 
(Compound chiral separation conditions and representative traces), and can be utilized to 
compare the enzymatic products to an absolute configuration authentic standard in future studies. 
The optical rotations of some isolated products were collected for additional characterization of 
their chirality. 
 
Ethyl 2-hexylcyclopropane-1-carboxylate (3a) 
 
3a was synthesized with procedure B from 1-octene 2a and 1 to give 3a as a 58:42 mixture of 
trans/cis-isomers. Both trans- and cis-3a are known compounds.15,16 
 
Cis-3a: 1H NMR (300 MHz, Chloroform-d) δ 4.13 (q, J = 7.1 Hz, 2H), 1.66 (ddd, J = 8.9, 7.8, 5.5 
Hz, 1H), 1.56 – 1.43 (m, 2H), 1.38 – 1.22 (m, 12H), 1.03 – 0.90 (m, 2H), 0.90 – 0.82 (m, 3H). 
 
Trans-3a: 1H NMR (300 MHz, Chloroform-d) δ 4.11 (q, J = 7.1 Hz, 2H), 1.36 – 1.22 (m, 15H), 
1.14 (dt, J = 8.7, 4.5 Hz, 1H), 0.90 – 0.84 (m, 3H), 0.68 (ddd, J = 7.9, 6.1, 4.0 Hz, 1H). HR-MS 
(FAB+): fragment ion, loss of ethoxy group [M ‒ CH3CH2O]+ C10H17O calculated 153.1279, found 
153.127. 
 
 
Ethyl 2-phenethylcyclopropane-1-carboxylate (3b) 
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3b was synthesized with procedure B from 4-phenyl-1-butene 2b and 1 to give 3b as a 57:43 
mixture of trans/cis-isomers. Cis-3b is a known compound.14 
 
Cis-3b: 1H NMR (300 MHz, Chloroform-d) δ 7.37 – 7.22 (m, 5H), 4.20 (q, J = 7.1 Hz, 2H), 2.70 
(t, J = 7.3 Hz, 2H), 1.93 (tq, J = 14.1, 6.7 Hz, 2H), 1.80 – 1.66 (m, 1H), 1.34 (td, J = 7.1, 0.7 Hz, 
4H), 1.14 – 0.96 (m, 2H). 13C NMR (75 MHz, Chloroform-d) δ 173.2, 142.1, 128.6, 128.4, 125.9, 
60.5, 36.0, 29.0, 21.5, 18.4, 14.5, 13.6. 
 
Trans-3b 1H NMR (400 MHz, Chloroform-d) δ 7.32 – 7.23 (m, 2H), 7.24 – 7.13 (m, 3H), 4.11 (q, 
J = 7.1 Hz, 2H), 2.72 (t, J = 7.7 Hz, 2H), 1.71 – 1.54 (m, 2H), 1.45 – 1.31 (m, 2H), 1.26 (t, J = 
7.1 Hz, 3H), 1.16 (ddd, J = 8.8, 4.8, 4.1 Hz, 1H), 0.69 (ddd, J = 8.2, 6.3, 4.1 Hz, 1H). 13C NMR 
(101 MHz, Chloroform-d) δ 174.5, 141.8, 128.5, 128.5, 126.0, 60.5, 35.6, 35.2, 22.6, 20.4, 15.6, 
14.4. HR-MS (FAB+): [M+H]+ C14H19O2, calculated 219.1385, found 219.1382. 
 
 
1-Benzyl 2-ethyl cyclopropane-1,2-dicarboxylate (3c) 
 
 
General procedure A only produced trace amounts of the cyclopropane product 3c. As each final 
protein variant produced 3c with high activity, preparative-scale reactions were carried out for 
each protein. The purified products were confirmed via NMR and used for chiral separation 
method development and analytical-scale calibration curves. 
 
Cis-3c (prepared from P411-UA V87C) 1H NMR (400 MHz, Chloroform-d) δ 7.42 – 7.28 (m, 5H), 
5.15 (d, J = 12.3 Hz, 1H), 5.10 (d, J = 12.3 Hz, 1H), 4.08 (qd, J = 7.1, 1.0 Hz, 2H), 2.16 – 1.99 
(m, 2H), 1.71 (td, J = 6.7, 5.0 Hz, 1H), 1.28 – 1.23 (m, 1H), 1.20 (t, J = 7.2 Hz, 3H). 13C NMR 
(101 MHz, Chloroform-d) δ 169.9, 169.9, 135.9, 128.7, 128.5, 128.4, 67.0, 61.2, 21.9, 21.7, 
14.3, 11.9. HR-MS: [M+H]+ C14H17O4,calculated 249.1127, found 249.1125. Cis-3c optical 
rotation from ApePgb AGW product: [α]D22 = 17.0 ° (c 0.1, EtOAc). Cis-3c optical rotation from 
P411-UA V87C product: [α]D22 = +9.8 ° (c 0.1, EtOAc). 
 
Trans-3c (prepared from P411-UA V87F) 1H NMR (400 MHz, Chloroform-d) δ 7.43 – 7.29 (m, 
5H), 5.13 (s, 2H), 4.14 (q, J = 7.1 Hz, 2H), 2.27 – 2.15 (m, 2H), 1.46 (ddd, J = 8.3, 6.2, 1.8 Hz, 
2H), 1.26 (t, J = 7.1 Hz, 3H).  13C NMR (101 MHz, Chloroform-d) δ 171.8, 171.8, 135.6, 128.8, 
128.5, 128.5, 67.0, 61.3, 22.7, 22.5, 15.7, 14.3. HR-MS : [M+H] + C14H17O4, calculated 249.1127, 
found 249.1123. Trans-3c optical rotation from P411-UA V87F product: [α]D22 = 124.1 ° (c 0.1, 
EtOAc). 
 
 
Ethyl 2-(4-bromobutyl)cyclopropane-1-carboxylate (3d) 
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Both cis- and trans-3d are known compounds.37 3d was synthesized with Procedure A from 6-
bromo-1-hexene 2d and EDA 1 to give 3d. The crude cis/trans ratio of this reaction was not 
determined. 
 
Cis-3d 1H NMR (400 MHz, Chloroform-d) δ 4.14 (q, J = 7.1 Hz, 2H), 3.40 (t, J = 6.8 Hz, 2H), 
1.93 – 1.80 (m, 2H), 1.74 – 1.38 (m, 4H), 1.56 (s, 1H), 1.33 – 1.15 (m, 4H), 1.02 (td, J = 8.0, 4.5 
Hz, 1H), 0.92 (ddd, J = 7.2, 5.4, 4.5 Hz, 1H). 13C NMR (101 MHz, Chloroform-d) δ 173.1, 60.5, 
34.0, 32.6, 28.4, 26.3, 21.7, 18.3, 14.5, 13.5. HR-MS (FAB+): Fragment ion, loss of ethoxy 
group [M - CH3CH2O]+ C8H1279BrO,calculated 203.0072, found 203.0026. 
 
3d fraction containing 71:29 trans/cis diastereomeric mixture, reporting shifts characterized as 
trans-3d.  1H NMR (400 MHz, Chloroform-d) δ 4.21 – 4.04 (m, 2H), 3.40 (td, J = 6.8, 3.6 Hz, 
2H), 1.94 – 1.79 (m, 2H), 1.72 – 1.46 (m, 3H), 1.39 – 1.31 (m, 2H), 1.31 – 1.19 (m, 4H), 1.22 – 
1.12 (m, 1H), 0.74 – 0.64 (m, 1H). 13C NMR (101 MHz, Chloroform-d) δ 174.5, 60.5, 33.8, 32.5, 
32.3, 27.8, 22.6, 20.3, 15.6, 14.4.  
 
 
Ethyl 2-cyclohexylcyclopropane-1-carboxylate (3e) 
 
 
Synthesized with general procedure A from vinylcyclohexane 2e and EDA 1 to give 3e. The crude 
trans/cis ratio of this reaction was not determined. Cis-3e is a known compound.14 
 
 
Cis-3e: 1H NMR (300 MHz, Chloroform-d) δ 4.18 – 4.04 (m, 1H), 1.85 – 1.51 (m, 6H), 1.29 – 
0.92 (m, 2H). 13C NMR (75 MHz, Chloroform-d) δ 173.2, 60.2, 35.8, 33.3, 33.2, 28.6, 26.4, 26.1, 
25.9, 17.9, 14.4, 12.5. HR-MS (FAB+): [M]+ C12H20O2, calculated 196.1463, found 196.1464. 
 
 
Ethyl spiro[2.5]octane-1-carboxylate (3f) 
 
Synthesized with general procedure A from methylenecyclohexane 2f and EDA 1. 3f is a known 
compound.38 
 
1H NMR (400 MHz, Chloroform-d) δ 4.11 (qd, J = 7.1, 1.0 Hz, 2H), 1.62 – 1.27 (m, 11H), 1.24 (t, 
J = 7.1 Hz, 3H), 1.06 (dd, J = 5.4, 4.3 Hz, 1H), 0.79 (dd, J = 7.8, 4.3 Hz, 1H). 13C NMR (101 
MHz, Chloroform-d) δ 173.1, 60.2, 37.4, 30.7, 28.8, 26.2 (2 overlapping carbons), 25.7, 25.7, 
20.6, 14.4. HR-MS (FAB+): [M]+ C11H18O2, calculated 182.1307, found 182.1282 
 
 
Ethyl 2-propionylcyclopropane-1-carboxylate (3g) 
 
 23 
 
Running general procedure B with 1-penten-3-one 2h produced no detectable cyclopropane 
product 3g; the primary products were diethyl fumarate, diethyl maleate, and an apparent 1,3-
dipolar [2+3] cycloaddition product (ethyl 3-propionyl-4,5-dihydro-1H-pyrazole-5-carboxylate). 
Trans-3g was synthesized on a 5 mmol scale with a racemic strategy adapted from the chiral 
synthesis previously reported.39 Co(II) tetraphenylporphyrin (5 mol%, 168 mg) and 1,1,-
dimethylaminopyridine (DMAP, 305 mg, 2.5 mmol) were added to a 40 mL scintillation vial with 
stir bar. The vial was sealed with a septum and placed under an Argon atmosphere. 
Dichloromethane (18 mL) was added, followed by 1-penten-3-one 2g (510 µL, 5 mmol). EDA 1 
(725 µL, 6 mmol) was added via syringe pump over 2 hours. The crude reaction mixture was 
concentrated in vacuo and separated via flash chromatography with a SNAP Ultra 25g column 
using a gradient of 0-20% diethyl ether in pentane. Fractions containing trans-3g were 
concentrated in vacuo to give the desired product. 
 
Trans-3g 1H NMR (400 MHz, Chloroform-d) δ 4.14 (q, J = 7.2 Hz, 2H), 2.63 (q, J = 7.3 Hz, 2H), 
2.49 – 2.39 (m, 1H), 2.21 – 2.11 (m, 1H), 1.45 – 1.35 (m, 2H), 1.27 (t, J = 7.1 Hz, 3H), 1.08 (t, J 
= 7.3 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 208.2, 172.3, 61.2, 37.3, 28.9, 24.1, 17.2, 
14.3, 7.8. HR-MS (ESI+): [M+Na]+ C9H14O3Na, calculated 193.0841 found 193.0819. 
 
Cis-3g was synthesized based on a modified literature procedure of the methyl ketone analog.40 
3-Oxabicyclo[3.1.0]hexane-2,4-dione (10 mmol) was added to anhydrous diethyl ether under 
Argon. Ethylmagnesium bromide (9 mL of 1 M in diethyl ether, diluted from 3 M solution in diethyl 
ether, 9 mmol) was added dropwise over 20 min at 78°C. The reaction mixture was allowed to 
warm to room temperature over 2 hours and stirred for 18 hours. The reaction was then quenched 
with aqueous ammonium chloride and extracted by diethyl ether (4 x 40 mL), dried over sodium 
sulfate and concentrated in vacuo. The crude product was used for the esterification step without 
further purification. Half of the crude product was dissolved in ethanol (20 mL), thionyl chloride (1 
mL) was added, and the reaction proceeded at room temperature for 12 hours. The reaction was 
then quenched with aqueous sodium bicarbonate and diluted with water, and extracted with 
diethyl ether. The crude mixture was purified via flash chromatography using a gradient of 0-50% 
diethyl ether in pentane. Fractions containing cis-3g were concentrated in vacuo to give the 
desired product.  
 
Cis-3g 1H NMR (400 MHz, Chloroform-d) δ 4.20 – 4.04 (m, 2H), 2.69 – 2.47 (m, 2H), 2.22 (ddd, 
J = 9.3, 8.2, 6.7 Hz, 1H), 2.08 (ddd, J = 9.2, 8.4, 6.6 Hz, 1H), 1.70 (tdd, J = 6.7, 4.7, 0.6 Hz, 1H), 
1.23 (t, J = 7.2 Hz, 3H), 1.22 – 1.15 (m, 1H), 1.07 (td, J = 7.3, 0.5 Hz, 3H). 13C NMR (101 MHz, 
Chloroform-d) δ 206.6, 170.1, 61.1, 36.9, 27.9, 23.4, 14.3, 12.2, 7.9.  
 
 
Ethyl 2-(pyridin-2-yl)cyclopropane-1-carboxylate (3h) 
 
 
Both trans- and cis-3h are known compounds.41 Cis- and trans-3h were produced by refluxing 2-
vinylpyridine 2h (10 mmol) with EDA 1 (10 mmol) in toluene (20 mL) overnight. The reaction 
yielded a 65:35 trans/cis mixture of diastereomers. The crude mixture was concentrated in vacuo 
and the product was purified using flash chromatography with a SNAP Ultra 10g Biotage column, 
0-100% hexane:EtOAc gradient. Fractions containing pure trans-3h and cis-3h were separable 
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and concentrated in vacuo to give the desired products (391.7 mg trans-3h, 290.7 mg cis-3h, 
36% yield). 
 
Cis-3h: 1H NMR (400 MHz, Chloroform-d) δ 8.49 (ddd, J = 4.9, 1.9, 0.9 Hz, 1H), 7.58 (td, J = 
7.7, 1.8 Hz, 1H), 7.32 – 7.22 (m, 1H), 7.10 (ddd, J = 7.4, 4.8, 1.1 Hz, 1H), 3.90 (qd, J = 7.2, 1.5 
Hz, 2H), 2.72 (td, J = 9.0, 7.6 Hz, 1H), 2.22 – 2.11 (m, 1H), 1.87 – 1.77 (m, 1H), 1.47 – 1.36 (m, 
1H), 1.02 (td, J = 7.1, 0.9 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 171.1, 156.7, 148.9, 
135.9, 123.6, 121.6, 60.3, 27.2, 21.7, 14.0, 11.7. 
 
Trans-3h 1H NMR (400 MHz, Chloroform-d) δ 8.43 (ddd, J = 4.9, 1.9, 1.0 Hz, 1H), 7.54 (td, J = 
7.7, 1.8 Hz, 1H), 7.21 (dt, J = 7.8, 1.1 Hz, 1H), 7.07 (ddd, J = 7.5, 4.9, 1.2 Hz, 1H), 4.15 (q, J = 
7.2 Hz, 2H), 2.56 (ddd, J = 8.9, 6.1, 3.9 Hz, 1H), 2.23 (ddd, J = 8.4, 5.5, 3.9 Hz, 1H), 1.59 (dddd, 
J = 13.8, 9.0, 5.8, 3.8 Hz, 2H), 1.26 (t, J = 7.1 Hz, 3H). 13C NMR (101 MHz, Chloroform-d) δ 
173.4, 158.9, 149.4, 136.0, 122.5, 121.3, 60.7, 27.2, 24.4, 17.3, 14.3. HR-MS (FAB+): [M]+ 
C11H13NO2, calculated 191.0946, found 191.092.  
 
 
Cis Ethyl 2-(6-hydroxyhexyl)cyclopropane-1-carboxylate (cis-3i) 
  
Cyclopropanation of the free alcohol 2i was performed via preparative-scale enzymatic reaction 
(ApePgb AGW) to give cis-3i.  
 
cis -3i 1H NMR (400 MHz, Chloroform-d) δ 4.12 (q, J = 7.1 Hz, 2H), 3.62 (t, J = 6.6 Hz, 2H), 1.78 
– 1.61 (broad m, 1H), 1.66 (ddd, J = 8.9, 7.8, 5.5 Hz, 1H), 1.60 – 1.43 (m, 4H), 1.41 – 1.29 (m, 
6H), 1.26 (t, J = 7.1 Hz, 3H), 1.25 – 1.16 (m, 1H), 1.05 – 0.95 (m, 1H), 0.91 (ddd, J = 7.2, 5.5, 
4.4 Hz, 1H). 13C NMR (101 MHz, Chloroform-d) δ 173.3, 63.1, 60.4, 32.8, 29.7, 29.2, 27.0, 25.8, 
22.1, 18.3, 14.5, 13.5. HR-MS (FAB+): [M+H]+ C12H23O3, calculated 215.1647, found 215.1648. 
 
 
Oct-7-en-1-yl 4-nitrobenzoate (2ia) 
  
7-Octen-1-ol 2i (577 mg, 4.5 mmol, 1.0 eq.) and triethylamine (0.82 mL, 1.3 eq.) were dissolved 
in anhydrous dichloromethane (45 mL). A solution of 4-nitrobenzoyl chloride (944 mg, 1.13 eq.) 
in anhydrous dichloromethane (5 mL) was added to the reaction. The resulting mixture was stirred 
at room temperature for 4 hours. The crude reaction mixture was extracted with dichloromethane 
and washed with brine and concentrated in vacuo. The product was purified by flash 
chromatography with a gradient of 0-8% ethyl acetate in hexane. Fractions containing 2ia were 
concentrated in vacuo to give the desired product (1.24 g, 99% yield). 
 
6-(2-(Ethoxycarbonyl)cyclopropyl)hexyl 4-nitrobenzoate (3ia) 
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3ia standard (racemic mixture) was synthesized as a mixture of trans/cis-isomers using general 
procedure B from 2ia and EDA 1 and purified via flash chromatography with a gradient of 0-13% 
ethyl acetate in hexane. Fractions containing trans-3ia and cis-3ia were separable and 
concentrated in vacuo to give the desired products (approximately 25% yield). 
 
Cis-3ia derivatized enzymatic product was prepared by protecting the preparative-scale 
enzymatic product 3i. 3i (~16 mg, ~0.058 mmol, 1.0 eq.), 4-nitrobenzoyl chloride (43 mg, 4.0 eq.), 
and triethylamine (80 μL, ~10.0 eq.) were added to anhydrous dichloromethane and the reaction 
proceeded at room temperature for 3 hours. The crude reaction mixture was concentrated in 
vacuo and purified by flash chromatography with a gradient of 0-13% ethyl acetate in hexane. 
Fractions containing cis-3ia were concentrated in vacuo to give the desired product. 
 
Cis-3ia 1H NMR (400 MHz, Chloroform-d) δ 8.33 – 8.25 (m, 2H), 8.25 – 8.17 (m, 2H), 4.36 (t, J 
= 6.7 Hz, 2H), 4.13 (q, J = 7.1 Hz, 2H), 1.82 – 1.74 (m, 2H), 1.77 – 1.62 (m, 1H), 1.49 – 1.32 (m, 
9H), 1.26 (t, J = 7.1 Hz, 3H), 1.00 (td, J = 8.2, 4.5 Hz, 1H), 0.94 – 0.87 (m, 1H). 13C NMR (101 
MHz, Chloroform-d) δ 173.2, 164.9, 150.6, 136.0, 130.8, 123.7, 66.2, 60.4, 29.6, 29.1, 28.7, 
27.0, 26.1, 22.0, 18.3, 14.5, 13.6. HR-MS (FAB+): [M+H]+ C19H26NO6 calculated 364.1760, 
found 364.1775. 
 
 
Cis 6-(2-(ethoxycarbonyl)cyclopropyl)hexanoic acid (cis-3j) 
  
Cyclopropanation of the free carboxylic acid 2j was performed via preparative-scale enzymatic 
reaction (ApePgb AGW) to give cis-3j. 
 
Cis-3j 1H NMR (400 MHz, Chloroform-d) δ 12.00 – 9.50 (broad, 1H), 4.13 (q, J = 7.1 Hz, 2H), 
2.38 – 2.29 (m, 2H), 1.71 – 1.58 (m, 3H), 1.58 – 1.40 (m, 2H), 1.40 – 1.30 (m, 4H), 1.29 – 1.16 
(m, 1H), 1.26 (t, 3H), 0.99 (td, J = 8.1, 4.4 Hz, 1H), 0.91 (ddd, J = 7.2, 5.4, 4.5 Hz, 1H). Trans-3j 
cyclopropane isomers (minor product in cis-3j 1H NMR): 1.14 (tdd, J = 7.1, 4.8, 2.5 Hz), 0.68 
(ddd, J = 7.8, 5.9, 4.0 Hz). 13C NMR (101 MHz, Chloroform-d) δ 179.4, 173.3, 60.4, 34.0, 29.4, 
28.8, 26.9, 24.8, 21.9, 18.3, 14.5, 13.5. HR-MS (FAB+): [M+H] + C12H21O4, calculated 229.1440, 
found 229.1448. 
 
Benzyl oct-7-enoate (2ja) 
 
2ja was produced by benzyl-protection of 7-octen-1-oic acid 2j. 2j (498 mg, 3.5 mmol, 1.0 eq.) 
and potassium carbonate (967 mg, 2.0 eq.) were added to anhydrous dimethylformamide (20 
mL). A solution of benzyl bromide (720 mg, 1.2 eq.) in anhydrous dimethylformamide (4 mL) was 
added to the reaction slowly over 10 min. The resulting reaction mixture was stirred at room 
temperature for 20 hours. The crude reaction mixture was extracted with diethyl ether, washed 
with brine, dried over sodium sulfate, and concentrated in vacuo. The product was purified via 
flash chromatography with hexane:ethyl acetate (20:1) as eluent. Fractions containing 2ja were 
concentrated in vacuo to give the desired product (805 mg, 99% yield). 
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Ethyl 2-(6-(benzyloxy)-6-oxohexyl)cyclopropane-1-carboxylate (3ja) 
 
3ja racemic standard was synthesized with a modification of general procedure B. 2ja (100 mg, 
~0.43 mmol) and EDA 1 (~5.0 eq) were added to dichloromethane with Rh2(OAc)4 (2 mol%) and 
the reaction proceeded at room temperature for 20 hours. The crude reaction mixture was 
concentrated in vacuo and purified via flash chromatography with a gradient of 0-20% ethyl 
acetate in hexane. Fractions containing trans-3ja and cis-3ja were separable and concentrated 
in vacuo to give the desired products (<15% yield). 
 
3ja derivatized enzymatic product was synthesized from the preparative-scale enzymatic reaction 
(ApePgb AGW) 3j. 3j (15 mg, ~0.065 mmol, 1.0 eq.) and potassium carbonate (27 mg, 3.0 eq.) 
were added to anhydrous dimethylformamide (2 mL). A solution of benzyl bromide (16 μL, 2.0 
eq.) in anhydrous dimethylformamide (0.5 mL) was added to the reaction slowly. The resulting 
reaction mixture was stirred at room temperature for 20 hours. The crude reaction mixture was 
extracted with diethyl ether, washed with brine, dried over sodium sulfate, and concentrated in 
vacuo. The product was purified via flash chromatography with hexane:ethyl acetate (10:1) as 
eluent. Fractions containing 3ja were concentrated in vacuo to give the desired product. 
 
Cis-3ja from 3j produced by ApePgb AGW. 1H NMR (400 MHz, Chloroform-d) δ 7.35 (s, 3H), 
7.41 – 7.27 (m, 2H), 5.11 (s, 2H), 4.17 – 4.06 (m, 2H), 2.35 (td, J = 7.5, 3.4 Hz, 2H), 1.69 – 1.59 
(m, 3H), 1.55 – 1.28 (m, 6H), 1.25 (t, J = 7.1 Hz, 3H), 1.20 (dtd, J = 8.6, 7.1, 1.5 Hz, 1H), 0.98 
(td, J = 8.1, 4.4 Hz, 1H), 0.90 (ddd, J = 7.3, 5.5, 4.5 Hz, 1H). 13C NMR (101 MHz, Chloroform-d) 
δ 173.8, 173.2, 136.2, 128.7, 128.3, 128.3, 66.2, 60.4, 34.4, 29.4, 28.9, 26.9, 25.1, 21.9, 18.3, 
14.5, 13.5. HR-MS (FAB+): [M+H]+ C19H27O4, calculated 319.1909, found 319.1903. 
 
Trans-3ja from Rh2(OAc)4-catalyzed reaction. 1H NMR (400 MHz, Chloroform-d) δ 7.35 (s, 2H), 
7.41 – 7.29 (m, 3H), 5.11 (s, 2H), 4.11 (qd, J = 7.2, 0.7 Hz, 2H), 2.35 (t, J = 7.5 Hz, 2H), 1.68 – 
1.59 (m, 3H), 1.45 – 1.29 (m, 7H), 1.25 (t, J = 7.1 Hz, 3H), 1.18 – 1.09 (m, 1H), 0.67 (ddd, J = 
7.8, 6.0, 4.1 Hz, 1H). 13C NMR (101 MHz, Chloroform-d) δ 174.6, 173.6, 136.1, 128.6, 128.2, 
66.1, 60.3, 34.2, 32.8, 28.8, 28.7, 24.9, 22.8, 20.2, 15.5, 14.3. 
 
 
Ethyl (E)-2-(prop-1-en-1-yl)cyclopropane-1-carboxylate (3k) 
 
Both trans- and cis-3k are known compounds.42 Terminal alkene cyclopropanation of (E)-penta-
1,3-diene 2k and EDA 1 accomplished via preparative-scale enzymatic reaction gave cis-3k 
(ApePgb AGW) and trans-3k (RmaNOD Q52V). 
 
Cis-3k 1H NMR (400 MHz, Chloroform-d) δ 5.66 (dq, J = 15.4, 6.5 Hz, 1H), 5.41 (ddq, J = 15.3, 
8.6, 1.7 Hz, 1H), 4.22 – 4.03 (m, 2H), 1.89 – 1.78 (m, 2H), 1.67 (dd, J = 6.5, 1.7 Hz, 3H), 1.26 (t, 
3H), 1.23 – 1.10 (m, 2H).  
 
Trans-3k 1H NMR (400 MHz, Chloroform-d) δ 5.60 (dqd, J = 15.1, 6.5, 0.8 Hz, 1H), 5.03 (ddq, J 
= 15.2, 8.3, 1.7 Hz, 1H), 4.12 (q, J = 7.1 Hz, 2H), 1.95 (dddd, J = 9.4, 8.5, 6.3, 4.0 Hz, 1H), 1.65 
(dd, J = 6.5, 1.7 Hz, 3H), 1.57 – 1.53 (m, 1H), 1.31 (ddd, J = 9.2, 5.1, 4.3 Hz, 1H), 1.26 (t, J = 
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7.1 Hz, 3H), 0.91 (ddd, J = 8.3, 6.3, 4.3 Hz, 1H). 13C NMR (101 MHz, Chloroform-d) δ 173.9, 
130.9, 126.1, 60.7, 25.0, 21.8, 17.9, 15.6, 14.4. HR-MS (EI+): [M]+ C9H14O2, calculated 
154.0994, found 154.0974. Trans-3k optical rotation from RmaNOD Q52V product: [α]D23 = 
+164 ° (c 0.1, EtOAc). 
 
 
Ethyl (Z)-2-(prop-1-en-1-yl)cyclopropane-1-carboxylate (3l) 
 
Both trans- and cis-3l are known compounds.42 General procedure A was used to produce a 
mixture of 8 possible cyclopropanes (internal and terminal) for chiral GC standard from (Z)-penta-
1,3-diene 2l and EDA 1. Stereoselective, terminal alkene cyclopropanation accomplished via 
preparative-scale enzymatic reaction (ApePgb AGW). 
 
Cis-3l 1H NMR (400 MHz, Chloroform-d) δ 5.56 (dqd, J = 10.9, 6.9, 1.1 Hz, 1H), 5.34 (ddq, J = 
11.0, 9.3, 1.8 Hz, 1H), 4.21 – 4.04 (m, 2H), 2.16 – 2.03 (m, 1H), 1.92 (ddd, J = 8.8, 7.8, 6.0 Hz, 
1H), 1.72 (dd, J = 6.8, 1.8 Hz, 3H), 1.25 (t, J = 7.1 Hz, 3H), 1.23 – 1.17 (m, 2H). 13C NMR (101 
MHz, Chloroform-d) δ 172.3, 127.2, 126.3, 60.5, 21.0, 19.2, 14.5, 14.5, 13.3. Cis-3l optical 
rotation from ApePgb AGW product: [α]D23 = 260 ° (c 0.1, EtOAc). 
 
 
Ethyl 2-(3-oxobutyl)cyclopropane-1-carboxylate (3m) 
 
Cis-3m is a known compound.16 General procedure B was used to produce a mixture of 55:45 
trans/cis 3m, and a preparative-scale enzymatic reaction (ApePgb AGW) produced cis-3m. 
 
Cis-3m 1H NMR (400 MHz, Chloroform-d) δ 4.13 (q, J = 7.1 Hz, 2H), 2.46 (td, J = 7.3, 2.3 Hz, 
2H), 2.13 (s, 3H), 1.94 – 1.62 (m, 3H), 1.26 (t, J = 7.1 Hz, 4H), 1.06 – 0.86 (m, 2H). 
13C NMR (101 MHz, Chloroform-d) δ 208.9, 173.2, 60.7, 43.7, 30.2, 21.8, 21.3, 18.6, 14.7, 13.8. 
HR-MS (FAB+): [M+H]+ C10H17O3, calculated 185.1178, found 185.1171. Cis-3m optical rotation 
from ApePgb AGW product: [α]D23 = 52 ° (c 0.1, EtOAc). 
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Compound chiral separation conditions and representative traces 
Chiral trace figures here are produced via Jupyter Notebook. The Jupyter notebook and raw data 
traces are available as supplemental files. 
 
Supplemental Table 9. Chromatographic separation conditions. Column dimensions: Cyclosil-
B 30 m length x 0.32 mm ID x 0.25 µm film thickness; Chiraldex G-TA 30 m length x 0.25 mm ID 
x 0.12 µm film thickness; DB-WAXETR (15 / 30 m) length x 0.32 mm ID x 0.25 µm film 
thickness; Chiralpak IC 4.6 mm x 250 mm x 5 µm; Chiralpak IA 4.6 mm x 250 mm x 5 µm. 
Compound Instrument / column Method Retention times 
3a GC-FID, Cyclosil-B 90°C isothermal 
Cis 67.9 min, 69.5 min; trans 
81.7 min, 83.5 min 
3b 
GC-FID, Cyclosil-B 
80°C hold 2 min, 30°C 
min–1 to 140°C hold 40 
min 
cis 30.2 min, 30.9 min; trans 
35.7 min (unresolved) 
HPLC, Chiralpak IC 
Hexane: 0.8% 
isopropanol isocratic 
cis 7.1 min, 7.3 min 
(unresolved); trans 8.9 min, 
10.3 min 
3c 
GC-FID, Cyclosil-B 
80°C hold 2 min, 30°C 
min–1 to 170°C hold 30 
min 
Trans 24.5 min (unresolved); 
cis 26.4 min, 26.8 min 
HPLC, Chiralpak IC 
Hexane:16% 
isopropanol isocratic 
Cis 4.6 min (unresolved; trans 
6.4 min, 7.2 min 
3d GC-FID, Chiraldex G-TA 
100°C, 2°C min–1 to 
170°C 
Cis 25.1 min, 25.3 min; trans 
27.1 min, 27.2 min 
3e GC-FID, Cyclosil-B 
80°C hold 2 min, 30°C 
min–1 to 100°C hold 80 
min 
Cis 44.7 min, 46.8 min; trans 
76.6 min, 78.2 min 
3f GC-FID, Chiraldex G-TA 80°C isothermal 50.05 min, 51.0 min 
3g 
HPLC, Chiralpak IC 
Hexane: 9% 
isopropanol isocratic 
Trans 8.7 min, 9.7 min (second 
peak coelution with EDA dimer) 
GC-FID, Cyclosil-B 
80°C hold 2 min, 30°C 
min–1 to 125°C hold 12 
min 
Cis 12.5 min, 12.7 min 
3h GC-FID, Cyclosil-B 
80°C hold 2 min, 20°C 
min–1 to 120°C, 6 °C 
min–1 to 180°C 
Trans 13.7 min, 13.8 min 
3i 
GC-FID, DB-WAXETR (30 
m) 
80°C hold 2 min, 10°C 
min–1 to 170°C 
2i 8.4 min; EDA dimer 
(byproducts) 8.9 min, 10.1 min; 
cis-3i 14.5 min, trans-3i 14.6 
min 
3ia HPLC, Chiralpak IA 
Hexane: 0.5% 
isopropanol isocratic 
Cis 8.7 min, 9.0 min 
3j 
GC-FID, DB-WAXETR (15 
m) 
90°C hold 2 min, 10°C 
min–1 to 250°C 
EDA dimer (byproducts) 5.0 
min, 6.2 min, 2j 9.7 min, cis-3j 
16.6 min, trans-3j 16.7 min 
3ja HPLC, Chiralpak IC 
Hexane: 1% 
isopropanol isocratic 
Cis 24.9 min, 26.2 min 
3k GC-FID, Cyclosil-B 
80°C hold 2 min, 5°C 
min–1 to 140°C 
Terminal cyclopropane 
products: cis 9.5 min, 9.6 min; 
trans 9.9 min, 10.1 min 
3l GC-FID, Cyclosil-B 
80°C hold 2 min, 10°C 
min–1 to 85°C hold 20 
min 
Terminal cyclopropane 
products: cis 15.8 min, 16.3 
min; trans 17.6 min, 20.4 min 
3m GC-FID, Chiraldex G-TA 90°C isothermal Cis 112.7 min, 114.6 min 
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Supplemental Figure 3. Representative GC trace of 3a (1-octene + EDA). Chiral GC trace of 
authentic standard (Rh2(OAc)4-catalyzed) and each of the final variants. 
 
Supplemental Figure 4. Representative GC trace of 3b (4-phenyl-1-butene + EDA). Chiral GC 
trace of 3b product formation. Trans-3b peaks (35.7 min) are not baseline separated.  
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Supplemental Figure 5. Representative HPLC trace of 3b (4-phenyl-1-butene + EDA). Chiral 
HPLC trace of 3b product formation. 
 
 
Supplemental Figure 6. Representative GC trace of 3c (benzyl acrylate + EDA). Trans-3c 
(24.5 min) was not resolved on the Cyclosil-B column.  
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Supplemental Figure 7. Representative HPLC trace of trans-3c (benzyl acrylate + EDA). 
Enzymatic samples were from purified, preparative-scale enzymatic reactions.  
 
 
 
Supplemental Figure 8. Representative GC trace of 3d (6-bromo-1-hexene + EDA).  
 32 
 
 
Supplemental Figure 9. Representative chiral GC trace of 3e (vinylcyclohexane + EDA). 
 
 
 
 
Supplemental Figure 10. Representative chiral GC trace of 3f (methylenecyclohexane + EDA). 
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Supplemental Figure 11. Representative chiral GC trace of cis-3g (1-penten-3-one + EDA). 
 
 
 
 
 
Supplemental Figure 12. Representative chiral GC trace of 3h (2-vinylpyridine + EDA).  
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Supplemental Figure 13. Representative achiral GC trace of 3i (7-octen-1-ol + EDA). Offset 
traces show 7-octen-1-ol starting material 2i, EDA dimers (diethyl fumarate and diethyl 
maleate), and the crude reaction mixture from ApePgb AGW-catalyzed preparative-scale 
reaction.  
 
 
 
Supplemental Figure 14. Chiral HPLC trace of 3ia. Conditions for the baseline separation of 
isomers were not found, but a spike-in of racemic standard into the ApePgb AGW-catalyzed 
preparative-scale reaction shows the first enantiomer peak was not previously observed and 
that the enzyme-catalyzed product has high enantiopurity. 
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Supplemental Figure 15. Representative achiral GC trace of 3j (7-octen-1-oic acid + EDA). 
Offset traces show 7-octen-1-oic acid starting material 2j, EDA dimers (diethyl fumarate and 
diethyl maleate), and the crude reaction mixture from ApePgb AGW-catalyzed preparative-scale 
reaction. 
 
 
 
Supplemental Figure 16. Chiral HPLC trace of 3ja. ApePgb AGW-catalyzed preparative-scale 
reaction was run at both concentrated (approximately 5 mg mL -1, green) and dilute 
(approximately 0.5 mg mL-1, red) conditions. 
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Supplemental Figure 17. Representative GC trace of 3k ((E)-penta-1,3-diene + EDA). Offset 
chiral GC-FID trace of 3k from the four final variants.  
 
 
Supplemental Figure 18. Representative GC trace of 3l ((Z)-penta-1,3-diene + EDA). Chiral 
GC-FID trace of 3l authentic standard; 3 of 4 enantiomeric pairs had separation; the fourth was 
an internal cyclopropanation product not observed in the enzymatic reactions (14 minutes). 
Offset chiral GC-FID trace of 3l from the four final variants.  
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Supplemental Figure 19. Representative chiral GC trace of cis-3m.  
 
 
Calibration curves for analytical-scale TTN determination 
Calibration curves were prepared with analogous conditions to the analytical scale reactions. 
Cyclopropane product standards were diluted in ethanol and added (20 µL) to M9-N buffer (380 
µL), with final concentrations of product ranging from 0 – 20 mM (with two to three technical 
replicates). The samples were worked up the same as analytical-scale reactions, by the addition 
of HCl (16 µL, 3 M stock) and internal standard (16 µL of 40 mM acetophenone in cyclohexane). 
Cyclohexane (700 µL) was added and the samples were transferred into 1.7 mL Eppendorf tubes 
for extraction. The extraction was carried out with a Retsch MM 301 mixing mill (1 minute, 30 Hz 
/ 1800 rpm). Samples were centrifuged at 20000×g for 5 minutes at RT and the organic layer was 
used for chromatographic analysis. Cyclopropane products for methylenecyclohexane 3g and 2-
vinylpyridine 3h were set up in the same way, with the exception of running ten single replicates 
over the 0 to 20 mM product range.  
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The ratio of the product area and internal standard (P/S ratio) was determined for each sample, 
and a linear regression was performed for the P/S ratio versus the known concentration in each 
reaction, with the y–intercept set to 0. The resulting slopes were used to determine the 
concentration of product in the analytical-scale reactions, which is in turn used to calculate the 
total turnover number (TTN) per enzyme. 
 
 
Supplemental Figure 20. Achiral GC calibration curve of 3a (1-octene + EDA). 
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Supplemental Figure 21. Achiral GC calibration curve of 3b (4-phenyl-1-butene + EDA). 
 
 
 
 
Supplemental Figure 22. Achiral GC calibration curve of 3c (benzyl acrylate + EDA). 
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Supplemental Figure 23. Achiral GC calibration curve of 3d (6-bromo-1-hexene + EDA).   
 
 
 
 
Supplemental Figure 24. Achiral GC calibration curve of 3e (vinylcyclohexane + EDA). 
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Supplemental Figure 25. Achiral GC calibration curve of 3f (methylenecyclohexane + EDA). 
 
 
Supplemental Figure 26. Achiral GC calibration curve of 3g (1-penten-3-one + EDA). 
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Supplemental Figure 27. Achiral GC calibration curve of 3h (2-vinylpyridine + EDA). 
 
 
Sequences of primers and variants 
 
Supplemental Table 10. Primers used in the protein engineering described in the report. These 
primers are also available as a supplemental csv file. 
 
Primer name Primer sequence 
ApePgb_Y60X_NDT_f TTGACTTGTGGNDTGGTTGGGTAGCATCAAATGAGC 
ApePgb_Y60X_VHG_f TTGACTTGTGGVHGGGTTGGGTAGCATCAAATGAGC 
ApePgb_Y60X_TGG_f TTGACTTGTGGTGGGGTTGGGTAGCATCAAATGAGC 
ApePgb_Y60X_univ_r CCACAAGTCAAGGATCTCATCAACTTGATC 
ApePgb_Y60G_W59X_NDT_f TTGATGAGATCCTTGACTTGNDTGGTGGTTGGGTAGCATC 
ApePgb_Y60G_W59X_VHG_f TTGATGAGATCCTTGACTTGVHGGGTGGTTGGGTAGCATC 
ApePgb_Y60G_W59X_TGG_f N/A; WT codon is TGG 
ApePgb_Y60G_W59X_univ_r CAAGTCAAGGATCTCATCAACTTGATCTTTCAGAACGTC 
ApePgb_F73X_NDT_f ATGAGCATTTGATTTATTACNDTTCCAATCCGGATACAGGAG 
ApePgb_F73X_VHG_f ATGAGCATTTGATTTATTACVHGTCCAATCCGGATACAGGAG 
ApePgb_F73X_TGG_f ATGAGCATTTGATTTATTACTGGTCCAATCCGGATACAGGAG 
ApePgb_F73X_univ_r GTAATAAATCAAATGCTCATTTGATGCTACCCAACC 
ApePgb_F93X_NDT_f TGGAACGTGTACGCGCTCGCNDTGGAGCCTGGATTCTGGACAC 
ApePgb_F93X_VHG_f TGGAACGTGTACGCGCTCGCVHGGGAGCCTGGATTCTGGACAC 
ApePgb_F93X_TGG_f TGGAACGTGTACGCGCTCGCTGGGGAGCCTGGATTCTGGACAC 
ApePgb_F93X_univ_r GCGAGCGCGTACACGTTCCAGGTATTCCTTAATAGGCTCTC 
ApePgb_F145X_NDT_f CACTTCGTTATCTTATCGCANDTATCTATCCTATCACCGCCAC 
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ApePgb_F145X_VHG_f CACTTCGTTATCTTATCGCAVHGATCTATCCTATCACCGCCAC 
ApePgb_F145X_TGG_f CACTTCGTTATCTTATCGCATGGATCTATCCTATCACCGCCAC 
ApePgb_F145X_univ_r TGCGATAAGATAACGAAGTGGGATATGGGGCACGGTGCGT 
RmaNOD_Y32X_NDT_f CGCCACGATGNDTCGGCTGCTTTTCGAACG 
RmaNOD_Y32X_VHG_f CGCCACGATGVHGCGGCTGCTTTTCGAACG 
RmaNOD_Y32X_TGG_f CGCCACGATGTGGCGGCTGCTTTTCGAACG 
RmaNOD_Y32X_univ_r CATCGTGGCGCTAATAGCGACTGAGTGTTTCTGC 
RmaNOD_Q52X_NDT_f CTTCCTGAGAGANDTATACACAAGCTTGCG 
RmaNOD_Q52X_VHG_f CTTCCTGAGAGAVHGATACACAAGCTTGCG 
RmaNOD_Q52X_TGG_f CTTCCTGAGAGATGGATACACAAGCTTGCG 
RmaNOD_Q52X_univ_r TCTCTCAGGAAGTTCAAACAAGCTCCGCG 
RmaNOD_V97X_NDT_f CCATTATCCGCTGNDTTGGGAATGTTTGAGAGACG 
RmaNOD_V97X_VHG_f CCATTATCCGCTGVHGTGGGAATGTTTGAGAGACG 
RmaNOD_V97X_TGG_f CCATTATCCGCTGTGGTGGGAATGTTTGAGAGACG 
RmaNOD_V97X_univ_r CAGCGGATAATGGACGGCCTGCACTCCTGC 
P411_UA_437X_438X_NDT_NDT_f GCTCGATATTAAAGAAACTNDTNDTTTAAAACCTAAAGGC 
P411_UA_437X_438X_NDT_ACN_f GCTCGATATTAAAGAAACTNDTACNTTAAAACCTAAAGGC 
P411_UA_437X_438X_NDT_CAR_f GCTCGATATTAAAGAAACTNDTCARTTAAAACCTAAAGGC 
P411_UA_437X_438X_univ_r AGTTTCTTTAATATCGAGCTCGTAGTTTGTATGATCTTC 
P411_UA_A328X_NDT_f GCTTATGGCCAACTNDTCCTGCGTTTTCC 
P411_UA_A328X_VHG_f GCTTATGGCCAACTVHGCCTGCGTTTTCC 
P411_UA_A328X_TGG_f GCTTATGGCCAACTTGGCCTGCGTTTTCC 
P411_UA_A328X_univ_r AGTTGGCCATAAGCGCAGCGCTTCG 
P411_UA_I263X_NDT_f CAAATTATTACATTCTTANDTGCGGGACACGAAGC 
P411_UA_I263X_VHG_f CAAATTATTACATTCTTAVHGGCGGGACACGAAGC 
P411_UA_I263X_TGG_f CAAATTATTACATTCTTATGGGCGGGACACGAAGC 
P411_UA_I263X_univ_r TAAGAATGTAATAATTTGATAGCGAATGTTCCCG 
P411_UA_V87X_NDT_f GCAGGAGACGGGTTANDTACAAGCTGGACGC 
P411_UA_V87X_VHG_f GCAGGAGACGGGTTAVHGACAAGCTGGACGC 
P411_UA_V87X_TGG_f GCAGGAGACGGGTTATGGACAAGCTGGACGC 
P411_UA_V87X_univ_r TAACCCGTCTCCTGCAAAATCACG 
P411_UA_L181X_NDT_f GTATGGTCCGTGCANDTGATGAAGTAATGAACAAG 
P411_UA_L181X_VHG_f GTATGGTCCGTGCAVHGGATGAAGTAATGAACAAG 
P411_UA_L181X_TGG_f GTATGGTCCGTGCATGGGATGAAGTAATGAACAAG 
P411_UA_L181X_univ_r TGCACGGACCATACTTATAATAAATGGATGAGG 
P411_UA_L75X_NDT_f GATAAAAACTTAAGTCAAGCGNDTAAATTTGCACGTGATTTTGCAGG 
P411_UA_L75X_VHG_f GATAAAAACTTAAGTCAAGCGVHGAAATTTGCACGTGATTTTGCAGG 
P411_UA_L75X_TGG_f GATAAAAACTTAAGTCAAGCGTGGAAATTTGCACGTGATTTTGCAGG 
P411_UA_L75X_univ_r CGCTTGACTTAAGTTTTTATCAAAGCGTGATTCATCGC 
P411_UA_E267X_NDT_f CTTAATCGCGGGACACNDTGCAACAAGTGGTCTTTTATC 
P411_UA_E267X_VHG_f CTTAATCGCGGGACACVHGGCAACAAGTGGTCTTTTATC 
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P411_UA_E267X_TGG_f CTTAATCGCGGGACACTGGGCAACAAGTGGTCTTTTATC 
P411_UA_E267X_univ_r GTGTCCCGCGATTAAGAATGTAATAATTTGATAGC 
pET_internal_primer_forward GCACTCTCAGTACAATCTGCTCTGATGCCGCATAGTTAAGCC  
pET_internal_primer_reverse GGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGC  
pET22_OPV_005 GAAATAATTTTGTTTAACTTTAAGAAGGAGATATACATATG 
pET22_OPV_006 GCCGGATCTCAGTGGTGGTGGTGGTGGTGCTCGAG 
pET22_OPV_007 CATATGTATATCTCCTTCTTAAAGTTAAACAAAATTATTTC 
pET22_OPV_008 CTCGAGCACCACCACCACCACCACTGAGATCCGGC 
 
 
Supplemental Table 11. Information on engineered proteins in the report. 
Protein Original organism Host strain Vector 
Mutation(s) 
with respect to 
WT 
ApePgb WT Aeropyrum pernix E. cloni EXPRESS BL21(DE3) pET22b(+)  
ApePgb Y60G Aeropyrum pernix E. cloni EXPRESS BL21(DE3) pET22b(+) Y60G 
ApePgb W59A 
Y60G 
Aeropyrum pernix E. cloni EXPRESS BL21(DE3) pET22b(+) W59A Y60G 
ApePgb W59A 
Y60G F145W 
("AGW") 
Aeropyrum pernix E. cloni EXPRESS BL21(DE3) pET22b(+) 
W59A Y60G 
F145W 
RmaNOD WT 
Rhodothermus 
marinus 
E. cloni EXPRESS BL21(DE3) pET22b(+)  
RmaNOD Q52V 
Rhodothermus 
marinus 
E. cloni EXPRESS BL21(DE3) pET22b(+) Q52V 
P411-CIS Bacillus megaterium E. cloni EXPRESS BL21(DE3) pET22b(+) 
V78A, F87V, 
P142S, T175I, 
A184V, S226R, 
H236Q, E252G, 
T268A, A290V, 
L353V, I366V, 
C400S, E442K 
P411-UA Bacillus megaterium E. cloni EXPRESS BL21(DE3) pET22b(+) 
P411-CIS, L75Y, 
L181I, L437F, 
T438Q 
P411-UA-V87C Bacillus megaterium E. cloni EXPRESS BL21(DE3) pET22b(+) 
P411-CIS, L75Y, 
V87C, L181I, 
L437F, T438Q 
P411-UA-V87F Bacillus megaterium E. cloni EXPRESS BL21(DE3) pET22b(+) 
P411-CIS, L75Y, 
V87F, L181I, 
L437F, T438Q 
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Supplemental Table 12. DNA sequences of reported biocatalysts. These sequences are also 
available as a supplemental csv file. 
Protein DNA sequence 
ApePgb 
WT 
ATGACTCCCTCGGACATCCCGGGATATGATTATGGGCGTGTCGAGAAGTCACCCATCACGGACCTTG
AGTTTGACCTTCTGAAGAAGACTGTCATGTTAGGTGAAAAGGACGTAATGTACTTGAAAAAGGCGTG
TGACGTTCTGAAAGATCAAGTTGATGAGATCCTTGACTTGTGGTATGGTTGGGTAGCATCAAATGAG
CATTTGATTTATTACTTCTCCAATCCGGATACAGGAGAGCCTATTAAGGAATACCTGGAACGTGTAC
GCGCTCGCTTTGGAGCCTGGATTCTGGACACTACCTGCCGCGACTATAACCGTGAATGGTTAGACTA
CCAGTACGAAGTTGGGCTTCGTCATCACCGTTCAAAGAAAGGGGTCACAGACGGAGTACGCACCGTG
CCCCATATCCCACTTCGTTATCTTATCGCATTTATCTATCCTATCACCGCCACTATCAAGCCATTTT
TGGCTAAGAAAGGTGGCTCTCCGGAAGACATCGAAGGGATGTACAACGCTTGGTTCAAGTCTGTAGT
TTTACAAGTTGCCATCTGGTCACACCCTTATACTAAGGAGAATGACTGGCTCGAGCACCACCACCAC
CACCACTGA 
ApePgb 
Y60G 
ATGACTCCCTCGGACATCCCGGGATATGATTATGGGCGTGTCGAGAAGTCACCCATCACGGACCTTG
AGTTTGACCTTCTGAAGAAGACTGTCATGTTAGGTGAAAAGGACGTAATGTACTTGAAAAAGGCGTG
TGACGTTCTGAAAGATCAAGTTGATGAGATCCTTGACTTGTGGGGTGGTTGGGTAGCATCAAATGAG
CATTTGATTTATTACTTCTCCAATCCGGATACAGGAGAGCCTATTAAGGAATACCTGGAACGTGTAC
GCGCTCGCTTTGGAGCCTGGATTCTGGACACTACCTGCCGCGACTATAACCGTGAATGGTTAGACTA
CCAGTACGAAGTTGGGCTTCGTCATCACCGTTCAAAGAAAGGGGTCACAGACGGAGTACGCACCGTG
CCCCATATCCCACTTCGTTATCTTATCGCATTTATCTATCCTATCACCGCCACTATCAAGCCATTTT
TGGCTAAGAAAGGTGGCTCTCCGGAAGACATCGAAGGGATGTACAACGCTTGGTTCAAGTCTGTAGT
TTTACAAGTTGCCATCTGGTCACACCCTTATACTAAGGAGAATGACTGGCTCGAGCACCACCACCAC
CACCACTGA 
ApePgb 
W59A 
Y60G 
ATGACTCCCTCGGACATCCCGGGATATGATTATGGGCGTGTCGAGAAGTCACCCATCACGGACCTTG
AGTTTGACCTTCTGAAGAAGACTGTCATGTTAGGTGAAAAGGACGTAATGTACTTGAAAAAGGCGTG
TGACGTTCTGAAAGATCAAGTTGATGAGATCCTTGACTTGGCGGGTGGTTGGGTAGCATCAAATGAG
CATTTGATTTATTACTTCTCCAATCCGGATACAGGAGAGCCTATTAAGGAATACCTGGAACGTGTAC
GCGCTCGCTTTGGAGCCTGGATTCTGGACACTACCTGCCGCGACTATAACCGTGAATGGTTAGACTA
CCAGTACGAAGTTGGGCTTCGTCATCACCGTTCAAAGAAAGGGGTCACAGACGGAGTACGCACCGTG
CCCCATATCCCACTTCGTTATCTTATCGCATTTATCTATCCTATCACCGCCACTATCAAGCCATTTT
TGGCTAAGAAAGGTGGCTCTCCGGAAGACATCGAAGGGATGTACAACGCTTGGTTCAAGTCTGTAGT
TTTACAAGTTGCCATCTGGTCACACCCTTATACTAAGGAGAATGACTGGCTCGAGCACCACCACCAC
CACCACTGA 
ApePgb 
W59A 
Y60G 
F145W 
("AGW") 
ATGACTCCCTCGGACATCCCGGGATATGATTATGGGCGTGTCGAGAAGTCACCCATCACGGACCTTG
AGTTTGACCTTCTGAAGAAGACTGTCATGTTAGGTGAAAAGGACGTAATGTACTTGAAAAAGGCGTG
TGACGTTCTGAAAGATCAAGTTGATGAGATCCTTGACTTGGCGGGTGGTTGGGTAGCATCAAATGAG
CATTTGATTTATTACTTCTCCAATCCGGATACAGGAGAGCCTATTAAGGAATACCTGGAACGTGTAC
GCGCTCGCTTTGGAGCCTGGATTCTGGACACTACCTGCCGCGACTATAACCGTGAATGGTTAGACTA
CCAGTACGAAGTTGGGCTTCGTCATCACCGTTCAAAGAAAGGGGTCACAGACGGAGTACGCACCGTG
CCCCATATCCCACTTCGTTATCTTATCGCATGGATCTATCCTATCACCGCCACTATCAAGCCATTTT
TGGCTAAGAAAGGTGGCTCTCCGGAAGACATCGAAGGGATGTACAACGCTTGGTTCAAGTCTGTAGT
TTTACAAGTTGCCATCTGGTCACACCCTTATACTAAGGAGAATGACTGGCTCGAGCACCACCACCAC
CACCACTGA 
RmaNOD 
WT 
ATGGCGCCGACCCTGTCGGAACAGACCCGTCAGTTGGTACGTGCGTCTGTGCCTGCACTGCAGAAAC
ACTCAGTCGCTATTAGCGCCACGATGTATCGGCTGCTTTTCGAACGGTATCCCGAAACGCGGAGCTT
GTTTGAACTTCCTGAGAGACAGATACACAAGCTTGCGTCGGCCCTGTTGGCCTACGCCCGTAGTATC
GACAACCCATCGGCGTTACAGGCGGCCATCCGCCGCATGGTGCTTTCCCACGCACGCGCAGGAGTGC
AGGCCGTCCATTATCCGCTGGTTTGGGAATGTTTGAGAGACGCTATAAAAGAAGTCCTGGGCCCGGA
TGCCACCGAGACCCTTCTGCAGGCGTGGAAGGAAGCCTATGATTTTTTAGCTCATTTACTGTCTACC
AAGGAAGCGCAAGTCTACGCTGTGTTAGCTGAACTCGAGCATCACCATCACCATCACTGA 
RmaNOD 
Q52V 
ATGGCGCCGACCCTGTCGGAACAGACCCGTCAGTTGGTACGTGCGTCTGTGCCTGCACTGCAGAAAC
ACTCAGTCGCTATTAGCGCCACGATGTATCGGCTGCTTTTCGAACGGTATCCCGAAACGCGGAGCTT
GTTTGAACTTCCTGAGAGAGTTATACACAAGCTTGCGTCGGCCCTGTTGGCCTACGCCCGTAGTATC
GACAACCCATCGGCGTTACAGGCGGCCATCCGCCGCATGGTGCTTTCCCACGCACGCGCAGGAGTGC
AGGCCGTCCATTATCCGCTGGTTTGGGAATGTTTGAGAGACGCTATAAAAGAAGTCCTGGGCCCGGA
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TGCCACCGAGACCCTTCTGCAGGCGTGGAAGGAAGCCTATGATTTTTTAGCTCATTTACTGTCTACC
AAGGAAGCGCAAGTCTACGCTGTGTTAGCTGAACTCGAGCACCACCACCACCACCACTGA 
P411-CIS 
ATGACAATTAAAGAAATGCCTCAGCCAAAAACGTTTGGAGAGCTTAAAAATTTACCGTTATTAAACA
CAGATAAACCGGTTCAAGCTTTGATGAAAATTGCGGATGAATTAGGAGAAATCTTTAAATTCGAGGC
GCCTGGTCGTGTAACGCGCTACTTATCAAGTCAGCGTCTAATTAAAGAAGCATGCGATGAATCACGC
TTTGATAAAAACTTAAGTCAAGCGCTGAAATTTGCACGTGATTTTGCAGGAGACGGGTTAGTCACAA
GCTGGACGCATGAAAAAAATTGGAAAAAAGCGCATAATATCTTACTTCCAAGCTTTAGTCAGCAGGC
AATGAAAGGCTATCATGCGATGATGGTCGATATCGCCGTGCAGCTTGTTCAAAAGTGGGAGCGTCTA
AATGCAGATGAGCATATTGAAGTATCGGAAGACATGACACGTTTAACGCTTGATACAATTGGTCTTT
GCGGCTTTAACTATCGCTTTAACAGCTTTTACCGAGATCAGCCTCATCCATTTATTATAAGTATGGT
CCGTGCACTGGATGAAGTAATGAACAAGCTGCAGCGAGCAAATCCAGACGACCCAGCTTATGATGAA
AACAAGCGCCAGTTTCAAGAAGATATCAAGGTGATGAACGACCTAGTAGATAAAATTATTGCAGATC
GCAAAGCAAGGGGTGAACAAAGCGATGATTTATTAACGCAGATGCTAAACGGAAAAGATCCAGAAAC
GGGTGAGCCGCTTGATGACGGGAACATTCGCTATCAAATTATTACATTCTTAATTGCGGGACACGAA
GCAACAAGTGGTCTTTTATCATTTGCGCTGTATTTCTTAGTGAAAAATCCACATGTATTACAAAAAG
TAGCAGAAGAAGCAGCACGAGTTCTAGTAGATCCTGTTCCAAGCTACAAACAAGTCAAACAGCTTAA
ATATGTCGGCATGGTCTTAAACGAAGCGCTGCGCTTATGGCCAACTGCTCCTGCGTTTTCCCTATAT
GCAAAAGAAGATACGGTGCTTGGAGGAGAATATCCTTTAGAAAAAGGCGACGAAGTAATGGTTCTGA
TTCCTCAGCTTCACCGTGATAAAACAGTTTGGGGAGACGATGTGGAGGAGTTCCGTCCAGAGCGTTT
TGAAAATCCAAGTGCGATTCCGCAGCATGCGTTTAAACCGTTTGGAAACGGTCAGCGTGCGTCTATC
GGTCAGCAGTTCGCTCTTCATGAAGCAACGCTGGTACTTGGTATGATGCTAAAACACTTTGACTTTG
AAGATCATACAAACTACGAGCTCGATATTAAAGAAACTTTAACGTTAAAACCTAAAGGCTTTGTGGT
AAAAGCAAAATCGAAAAAAATTCCGCTTGGCGGTATTCCTTCACCTAGCACTGAACAGTCTGCTAAA
AAAGTACGCAAAAAGGCAGAAAACGCTCATAATACGCCGCTGCTTGTGCTATACGGTTCAAATATGG
GTACCGCTGAAGGAACGGCGCGTGATTTAGCAGATATTGCAATGAGCAAAGGATTTGCACCGCAGGT
CGCAACGCTTGATTCACACGCCGGAAATCTTCCGCGCGAAGGAGCTGTATTAATTGTAACGGCGTCT
TATAACGGTCATCCGCCTGATAACGCAAAGCAATTTGTCGACTGGTTAGACCAAGCGTCTGCTGATG
AAGTAAAAGGCGTTCGCTACTCCGTATTTGGATGCGGCGATAAAAACTGGGCTACTACGTATCAAAA
AGTGCCTGCTTTTATCGATGAAACGCTTGCCGCTAAAGGGGCAGAAAACATCGCTGACCGCGGTGAA
GCAGATGCAAGCGACGACTTTGAAGGCACATATGAAGAATGGCGTGAACATATGTGGAGTGACGTAG
CAGCCTACTTTAACCTCGACATTGAAAACAGTGAAGATAATAAATCTACTCTTTCACTTCAATTTGT
CGACAGCGCCGCGGATATGCCGCTTGCGAAAATGCACGGTGCGTTTTCAACGAACGTCGTAGCAAGC
AAAGAACTTCAACAGCCAGGCAGTGCACGAAGCACGCGACATCTTGAAATTGAACTTCCAAAAGAAG
CTTCTTATCAAGAAGGAGATCATTTAGGTGTTATTCCTCGCAACTATGAAGGAATAGTAAACCGTGT
AACAGCAAGGTTCGGCCTAGATGCATCACAGCAAATCCGTCTGGAAGCAGAAGAAGAAAAATTAGCT
CATTTGCCACTCGCTAAAACAGTATCCGTAGAAGAGCTTCTGCAATACGTGGAGCTTCAAGATCCTG
TTACGCGCACGCAGCTTCGCGCAATGGCTGCTAAAACGGTCTGCCCGCCGCATAAAGTAGAGCTTGA
AGCCTTGCTTGAAAAGCAAGCCTACAAAGAACAAGTGCTGGCAAAACGTTTAACAATGCTTGAACTG
CTTGAAAAATACCCGGCGTGTGAAATGAAATTCAGCGAATTTATCGCCCTTCTGCCAAGCATACGCC
CGCGCTATTACTCGATTTCTTCATCACCTCGTGTCGATGAAAAACAAGCAAGCATCACGGTCAGCGT
TGTCTCAGGAGAAGCGTGGAGCGGATATGGAGAATATAAAGGAATTGCGTCGAACTATCTTGCCGAG
CTGCAAGAAGGAGATACGATTACGTGCTTTATTTCCACACCGCAGTCAGAATTTACGCTGCCAAAAG
ACCCTGAAACGCCGCTTATCATGGTCGGACCGGGAACAGGCGTCGCGCCGTTTAGAGGCTTTGTGCA
GGCGCGCAAACAGCTAAAAGAACAAGGACAGTCACTTGGAGAAGCACATTTATACTTCGGCTGCCGT
TCACCTCATGAAGACTATCTGTATCAAGAAGAGCTTGAAAACGCCCAAAGCGAAGGCATCATTACGC
TTCATACCGCTTTTTCTCGCATGCCAAATCAGCCGAAAACATACGTTCAGCACGTAATGGAACAAGA
CGGCAAGAAATTGATTGAACTTCTTGATCAAGGAGCGCACTTCTATATTTGCGGAGACGGAAGCCAA
ATGGCACCTGCCGTTGAAGCAACGCTTATGAAAAGCTATGCTGACGTTCACCAAGTGAGTGAAGCAG
ACGCTCGCTTATGGCTGCAGCAGCTAGAAGAAAAAGGCCGATACGCAAAAGACGTGTGGGCTGGGCT
CGAGCACCACCACCACCACCACTGAGATCCGGCTGCTAACAAAGCCCGAA 
P411-UA 
ATGACAATTAAAGAAATGCCTCAGCCAAAAACGTTTGGAGAGCTTAAAAATTTACCGTTATTAAACA
CAGATAAACCGGTTCAAGCTTTGATGAAAATTGCGGATGAATTAGGAGAAATCTTTAAATTCGAGGC
GCCTGGTCGTGTAACGCGCTACTTATCAAGTCAGCGTCTAATTAAAGAAGCATGCGATGAATCACGC
TTTGATAAAAACTTAAGTCAAGCGTATAAATTTGCACGTGATTTTGCAGGAGACGGGTTAGTGACAA
GCTGGACGCATGAAAAAAATTGGAAAAAAGCGCATAATATCTTACTTCCAAGCTTTAGTCAGCAGGC
AATGAAAGGCTATCATGCGATGATGGTCGATATCGCCGTGCAGCTTGTTCAAAAGTGGGAGCGTCTA
AATGCAGATGAGCATATTGAAGTATCGGAAGACATGACACGTTTAACGCTTGATACAATTGGTCTTT
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GCGGCTTTAACTATCGCTTTAACAGCTTTTACCGAGATCAGCCTCATCCATTTATTATAAGTATGGT
CCGTGCAATTGATGAAGTAATGAACAAGCTGCAGCGAGCAAATCCAGACGACCCAGCTTATGATGAA
AACAAGCGCCAGTTTCAAGAAGATATCAAGGTGATGAACGACCTAGTAGATAAAATTATTGCAGATC
GCAAAGCAAGGGGTGAACAAAGCGATGATTTATTAACGCAGATGCTAAACGGAAAAGATCCAGAAAC
GGGTGAGCCGCTTGATGACGGGAACATTCGCTATCAAATTATTACATTCTTAATTGCGGGACACGAA
GCAACAAGTGGTCTTTTATCATTTGCGCTGTATTTCTTAGTGAAAAATCCACATGTATTACAAAAAG
TAGCAGAAGAAGCAGCACGAGTTCTAGTAGATCCTGTTCCAAGCTACAAACAAGTCAAACAGCTTAA
ATATGTCGGCATGGTCTTAAACGAAGCGCTGCGCTTATGGCCAACTGCTCCTGCGTTTTCCCTATAT
GCAAAAGAAGATACGGTGCTTGGAGGAGAATATCCTTTAGAAAAAGGCGACGAAGTAATGGTTCTGA
TTCCTCAGCTTCACCGTGATAAAACAGTTTGGGGAGACGATGTGGAGGAGTTCCGTCCAGAGCGTTT
TGAAAATCCAAGTGCGATTCCGCAGCATGCGTTTAAACCGTTTGGAAACGGTCAGCGTGCGTCTATC
GGTCAGCAGTTCGCTCTTCATGAAGCAACGCTGGTACTTGGTATGATGCTAAAACACTTTGACTTTG
AAGATCATACAAACTACGAGCTCGATATTAAAGAAACTTTTCAGTTAAAACCTAAAGGCTTTGTGGT
AAAAGCAAAATCGAAAAAAATTCCGCTTGGCGGTATTCCTTCACCTAGCACTGAACAGTCTGCTAAA
AAAGTACGCAAAAAGGCAGAAAACGCTCATAATACGCCGCTGCTTGTGCTATACGGTTCAAATATGG
GTACCGCTGAAGGAACGGCGCGTGATTTAGCAGATATTGCAATGAGCAAAGGATTTGCACCGCAGGT
CGCAACGCTTGATTCACACGCCGGAAATCTTCCGCGCGAAGGAGCTGTATTAATTGTAACGGCGTCT
TATAACGGTCATCCGCCTGATAACGCAAAGCAATTTGTCGACTGGTTAGACCAAGCGTCTGCTGATG
AAGTAAAAGGCGTTCGCTACTCCGTATTTGGATGCGGCGATAAAAACTGGGCTACTACGTATCAAAA
AGTGCCTGCTTTTATCGATGAAACGCTTGCCGCTAAAGGGGCAGAAAACATCGCTGACCGCGGTGAA
GCAGATGCAAGCGACGACTTTGAAGGCACATATGAAGAATGGCGTGAACATATGTGGAGTGACGTAG
CAGCCTACTTTAACCTCGACATTGAAAACAGTGAAGATAATAAATCTACTCTTTCACTTCAATTTGT
CGACAGCGCCGCGGATATGCCGCTTGCGAAAATGCACGGTGCGTTTTCAACGAACGTCGTAGCAAGC
AAAGAACTTCAACAGCCAGGCAGTGCACGAAGCACGCGACATCTTGAAATTGAACTTCCAAAAGAAG
CTTCTTATCAAGAAGGAGATCATTTAGGTGTTATTCCTCGCAACTATGAAGGAATAGTAAACCGTGT
AACAGCAAGGTTCGGCCTAGATGCATCACAGCAAATCCGTCTGGAAGCAGAAGAAGAAAAATTAGCT
CATTTGCCACTCGCTAAAACAGTATCCGTAGAAGAGCTTCTGCAATACGTGGAGCTTCAAGATCCTG
TTACGCGCACGCAGCTTCGCGCAATGGCTGCTAAAACGGTCTGCCCGCCGCATAAAGTAGAGCTTGA
AGCCTTGCTTGAAAAGCAAGCCTACAAAGAACAAGTGCTGGCAAAACGTTTAACAATGCTTGAACTG
CTTGAAAAATACCCGGCGTGTGAAATGAAATTCAGCGAATTTATCGCCCTTCTGCCAAGCATACGCC
CGCGCTATTACTCGATTTCTTCATCACCTCGTGTCGATGAAAAACAAGCAAGCATCACGGTCAGCGT
TGTCTCAGGAGAAGCGTGGAGCGGATATGGAGAATATAAAGGAATTGCGTCGAACTATCTTGCCGAG
CTGCAAGAAGGAGATACGATTACGTGCTTTATTTCCACACCGCAGTCAGAATTTACGCTGCCAAAAG
ACCCTGAAACGCCGCTTATCATGGTCGGACCGGGAACAGGCGTCGCGCCGTTTAGAGGCTTTGTGCA
GGCGCGCAAACAGCTAAAAGAACAAGGACAGTCACTTGGAGAAGCACATTTATACTTCGGCTGCCGT
TCACCTCATGAAGACTATCTGTATCAAGAAGAGCTTGAAAACGCCCAAAGCGAAGGCATCATTACGC
TTCATACCGCTTTTTCTCGCATGCCAAATCAGCCGAAAACATACGTTCAGCACGTAATGGAACAAGA
CGGCAAGAAATTGATTGAACTTCTTGATCAAGGAGCGCACTTCTATATTTGCGGAGACGGAAGCCAA
ATGGCACCTGCCGTTGAAGCAACGCTTATGAAAAGCTATGCTGACGTTCACCAAGTGAGTGAAGCAG
ACGCTCGCTTATGGCTGCAGCAGCTAGAAGAAAAAGGCCGATACGCAAAAGACGTGTGGGCTGGGCT
CGAGCACCACCACCACCACCACTGA 
P411-
UA-V87C 
ATGACAATTAAAGAAATGCCTCAGCCAAAAACGTTTGGAGAGCTTAAAAATTTACCGTTATTAAACA
CAGATAAACCGGTTCAAGCTTTGATGAAAATTGCGGATGAATTAGGAGAAATCTTTAAATTCGAGGC
GCCTGGTCGTGTAACGCGCTACTTATCAAGTCAGCGTCTAATTAAAGAAGCATGCGATGAATCACGC
TTTGATAAAAACTTAAGTCAAGCGTATAAATTTGCACGTGATTTTGCAGGAGACGGGTTATGTACAA
GCTGGACGCATGAAAAAAATTGGAAAAAAGCGCATAATATCTTACTTCCAAGCTTTAGTCAGCAGGC
AATGAAAGGCTATCATGCGATGATGGTCGATATCGCCGTGCAGCTTGTTCAAAAGTGGGAGCGTCTA
AATGCAGATGAGCATATTGAAGTATCGGAAGACATGACACGTTTAACGCTTGATACAATTGGTCTTT
GCGGCTTTAACTATCGCTTTAACAGCTTTTACCGAGATCAGCCTCATCCATTTATTATAAGTATGGT
CCGTGCAATTGATGAAGTAATGAACAAGCTGCAGCGAGCAAATCCAGACGACCCAGCTTATGATGAA
AACAAGCGCCAGTTTCAAGAAGATATCAAGGTGATGAACGACCTAGTAGATAAAATTATTGCAGATC
GCAAAGCAAGGGGTGAACAAAGCGATGATTTATTAACGCAGATGCTAAACGGAAAAGATCCAGAAAC
GGGTGAGCCGCTTGATGACGGGAACATTCGCTATCAAATTATTACATTCTTAATTGCGGGACACGAA
GCAACAAGTGGTCTTTTATCATTTGCGCTGTATTTCTTAGTGAAAAATCCACATGTATTACAAAAAG
TAGCAGAAGAAGCAGCACGAGTTCTAGTAGATCCTGTTCCAAGCTACAAACAAGTCAAACAGCTTAA
ATATGTCGGCATGGTCTTAAACGAAGCGCTGCGCTTATGGCCAACTGCTCCTGCGTTTTCCCTATAT
GCAAAAGAAGATACGGTGCTTGGAGGAGAATATCCTTTAGAAAAAGGCGACGAAGTAATGGTTCTGA
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TTCCTCAGCTTCACCGTGATAAAACAGTTTGGGGAGACGATGTGGAGGAGTTCCGTCCAGAGCGTTT
TGAAAATCCAAGTGCGATTCCGCAGCATGCGTTTAAACCGTTTGGAAACGGTCAGCGTGCGTCTATC
GGTCAGCAGTTCGCTCTTCATGAAGCAACGCTGGTACTTGGTATGATGCTAAAACACTTTGACTTTG
AAGATCATACAAACTACGAGCTCGATATTAAAGAAACTTTTCAGTTAAAACCTAAAGGCTTTGTGGT
AAAAGCAAAATCGAAAAAAATTCCGCTTGGCGGTATTCCTTCACCTAGCACTGAACAGTCTGCTAAA
AAAGTACGCAAAAAGGCAGAAAACGCTCATAATACGCCGCTGCTTGTGCTATACGGTTCAAATATGG
GTACCGCTGAAGGAACGGCGCGTGATTTAGCAGATATTGCAATGAGCAAAGGATTTGCACCGCAGGT
CGCAACGCTTGATTCACACGCCGGAAATCTTCCGCGCGAAGGAGCTGTATTAATTGTAACGGCGTCT
TATAACGGTCATCCGCCTGATAACGCAAAGCAATTTGTCGACTGGTTAGACCAAGCGTCTGCTGATG
AAGTAAAAGGCGTTCGCTACTCCGTATTTGGATGCGGCGATAAAAACTGGGCTACTACGTATCAAAA
AGTGCCTGCTTTTATCGATGAAACGCTTGCCGCTAAAGGGGCAGAAAACATCGCTGACCGCGGTGAA
GCAGATGCAAGCGACGACTTTGAAGGCACATATGAAGAATGGCGTGAACATATGTGGAGTGACGTAG
CAGCCTACTTTAACCTCGACATTGAAAACAGTGAAGATAATAAATCTACTCTTTCACTTCAATTTGT
CGACAGCGCCGCGGATATGCCGCTTGCGAAAATGCACGGTGCGTTTTCAACGAACGTCGTAGCAAGC
AAAGAACTTCAACAGCCAGGCAGTGCACGAAGCACGCGACATCTTGAAATTGAACTTCCAAAAGAAG
CTTCTTATCAAGAAGGAGATCATTTAGGTGTTATTCCTCGCAACTATGAAGGAATAGTAAACCGTGT
AACAGCAAGGTTCGGCCTAGATGCATCACAGCAAATCCGTCTGGAAGCAGAAGAAGAAAAATTAGCT
CATTTGCCACTCGCTAAAACAGTATCCGTAGAAGAGCTTCTGCAATACGTGGAGCTTCAAGATCCTG
TTACGCGCACGCAGCTTCGCGCAATGGCTGCTAAAACGGTCTGCCCGCCGCATAAAGTAGAGCTTGA
AGCCTTGCTTGAAAAGCAAGCCTACAAAGAACAAGTGCTGGCAAAACGTTTAACAATGCTTGAACTG
CTTGAAAAATACCCGGCGTGTGAAATGAAATTCAGCGAATTTATCGCCCTTCTGCCAAGCATACGCC
CGCGCTATTACTCGATTTCTTCATCACCTCGTGTCGATGAAAAACAAGCAAGCATCACGGTCAGCGT
TGTCTCAGGAGAAGCGTGGAGCGGATATGGAGAATATAAAGGAATTGCGTCGAACTATCTTGCCGAG
CTGCAAGAAGGAGATACGATTACGTGCTTTATTTCCACACCGCAGTCAGAATTTACGCTGCCAAAAG
ACCCTGAAACGCCGCTTATCATGGTCGGACCGGGAACAGGCGTCGCGCCGTTTAGAGGCTTTGTGCA
GGCGCGCAAACAGCTAAAAGAACAAGGACAGTCACTTGGAGAAGCACATTTATACTTCGGCTGCCGT
TCACCTCATGAAGACTATCTGTATCAAGAAGAGCTTGAAAACGCCCAAAGCGAAGGCATCATTACGC
TTCATACCGCTTTTTCTCGCATGCCAAATCAGCCGAAAACATACGTTCAGCACGTAATGGAACAAGA
CGGCAAGAAATTGATTGAACTTCTTGATCAAGGAGCGCACTTCTATATTTGCGGAGACGGAAGCCAA
ATGGCACCTGCCGTTGAAGCAACGCTTATGAAAAGCTATGCTGACGTTCACCAAGTGAGTGAAGCAG
ACGCTCGCTTATGGCTGCAGCAGCTAGAAGAAAAAGGCCGATACGCAAAAGACGTGTGGGCTGGGCT
CGAGCACCACCACCACCACCACTGA 
P411-
UA-V87F 
ATGACAATTAAAGAAATGCCTCAGCCAAAAACGTTTGGAGAGCTTAAAAATTTACCGTTATTAAACA
CAGATAAACCGGTTCAAGCTTTGATGAAAATTGCGGATGAATTAGGAGAAATCTTTAAATTCGAGGC
GCCTGGTCGTGTAACGCGCTACTTATCAAGTCAGCGTCTAATTAAAGAAGCATGCGATGAATCACGC
TTTGATAAAAACTTAAGTCAAGCGTATAAATTTGCACGTGATTTTGCAGGAGACGGGTTATTTACAA
GCTGGACGCATGAAAAAAATTGGAAAAAAGCGCATAATATCTTACTTCCAAGCTTTAGTCAGCAGGC
AATGAAAGGCTATCATGCGATGATGGTCGATATCGCCGTGCAGCTTGTTCAAAAGTGGGAGCGTCTA
AATGCAGATGAGCATATTGAAGTATCGGAAGACATGACACGTTTAACGCTTGATACAATTGGTCTTT
GCGGCTTTAACTATCGCTTTAACAGCTTTTACCGAGATCAGCCTCATCCATTTATTATAAGTATGGT
CCGTGCAATTGATGAAGTAATGAACAAGCTGCAGCGAGCAAATCCAGACGACCCAGCTTATGATGAA
AACAAGCGCCAGTTTCAAGAAGATATCAAGGTGATGAACGACCTAGTAGATAAAATTATTGCAGATC
GCAAAGCAAGGGGTGAACAAAGCGATGATTTATTAACGCAGATGCTAAACGGAAAAGATCCAGAAAC
GGGTGAGCCGCTTGATGACGGGAACATTCGCTATCAAATTATTACATTCTTAATTGCGGGACACGAA
GCAACAAGTGGTCTTTTATCATTTGCGCTGTATTTCTTAGTGAAAAATCCACATGTATTACAAAAAG
TAGCAGAAGAAGCAGCACGAGTTCTAGTAGATCCTGTTCCAAGCTACAAACAAGTCAAACAGCTTAA
ATATGTCGGCATGGTCTTAAACGAAGCGCTGCGCTTATGGCCAACTGCTCCTGCGTTTTCCCTATAT
GCAAAAGAAGATACGGTGCTTGGAGGAGAATATCCTTTAGAAAAAGGCGACGAAGTAATGGTTCTGA
TTCCTCAGCTTCACCGTGATAAAACAGTTTGGGGAGACGATGTGGAGGAGTTCCGTCCAGAGCGTTT
TGAAAATCCAAGTGCGATTCCGCAGCATGCGTTTAAACCGTTTGGAAACGGTCAGCGTGCGTCTATC
GGTCAGCAGTTCGCTCTTCATGAAGCAACGCTGGTACTTGGTATGATGCTAAAACACTTTGACTTTG
AAGATCATACAAACTACGAGCTCGATATTAAAGAAACTTTTCAGTTAAAACCTAAAGGCTTTGTGGT
AAAAGCAAAATCGAAAAAAATTCCGCTTGGCGGTATTCCTTCACCTAGCACTGAACAGTCTGCTAAA
AAAGTACGCAAAAAGGCAGAAAACGCTCATAATACGCCGCTGCTTGTGCTATACGGTTCAAATATGG
GTACCGCTGAAGGAACGGCGCGTGATTTAGCAGATATTGCAATGAGCAAAGGATTTGCACCGCAGGT
CGCAACGCTTGATTCACACGCCGGAAATCTTCCGCGCGAAGGAGCTGTATTAATTGTAACGGCGTCT
TATAACGGTCATCCGCCTGATAACGCAAAGCAATTTGTCGACTGGTTAGACCAAGCGTCTGCTGATG
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AAGTAAAAGGCGTTCGCTACTCCGTATTTGGATGCGGCGATAAAAACTGGGCTACTACGTATCAAAA
AGTGCCTGCTTTTATCGATGAAACGCTTGCCGCTAAAGGGGCAGAAAACATCGCTGACCGCGGTGAA
GCAGATGCAAGCGACGACTTTGAAGGCACATATGAAGAATGGCGTGAACATATGTGGAGTGACGTAG
CAGCCTACTTTAACCTCGACATTGAAAACAGTGAAGATAATAAATCTACTCTTTCACTTCAATTTGT
CGACAGCGCCGCGGATATGCCGCTTGCGAAAATGCACGGTGCGTTTTCAACGAACGTCGTAGCAAGC
AAAGAACTTCAACAGCCAGGCAGTGCACGAAGCACGCGACATCTTGAAATTGAACTTCCAAAAGAAG
CTTCTTATCAAGAAGGAGATCATTTAGGTGTTATTCCTCGCAACTATGAAGGAATAGTAAACCGTGT
AACAGCAAGGTTCGGCCTAGATGCATCACAGCAAATCCGTCTGGAAGCAGAAGAAGAAAAATTAGCT
CATTTGCCACTCGCTAAAACAGTATCCGTAGAAGAGCTTCTGCAATACGTGGAGCTTCAAGATCCTG
TTACGCGCACGCAGCTTCGCGCAATGGCTGCTAAAACGGTCTGCCCGCCGCATAAAGTAGAGCTTGA
AGCCTTGCTTGAAAAGCAAGCCTACAAAGAACAAGTGCTGGCAAAACGTTTAACAATGCTTGAACTG
CTTGAAAAATACCCGGCGTGTGAAATGAAATTCAGCGAATTTATCGCCCTTCTGCCAAGCATACGCC
CGCGCTATTACTCGATTTCTTCATCACCTCGTGTCGATGAAAAACAAGCAAGCATCACGGTCAGCGT
TGTCTCAGGAGAAGCGTGGAGCGGATATGGAGAATATAAAGGAATTGCGTCGAACTATCTTGCCGAG
CTGCAAGAAGGAGATACGATTACGTGCTTTATTTCCACACCGCAGTCAGAATTTACGCTGCCAAAAG
ACCCTGAAACGCCGCTTATCATGGTCGGACCGGGAACAGGCGTCGCGCCGTTTAGAGGCTTTGTGCA
GGCGCGCAAACAGCTAAAAGAACAAGGACAGTCACTTGGAGAAGCACATTTATACTTCGGCTGCCGT
TCACCTCATGAAGACTATCTGTATCAAGAAGAGCTTGAAAACGCCCAAAGCGAAGGCATCATTACGC
TTCATACCGCTTTTTCTCGCATGCCAAATCAGCCGAAAACATACGTTCAGCACGTAATGGAACAAGA
CGGCAAGAAATTGATTGAACTTCTTGATCAAGGAGCGCACTTCTATATTTGCGGAGACGGAAGCCAA
ATGGCACCTGCCGTTGAAGCAACGCTTATGAAAAGCTATGCTGACGTTCACCAAGTGAGTGAAGCAG
ACGCTCGCTTATGGCTGCAGCAGCTAGAAGAAAAAGGCCGATACGCAAAAGACGTGTGGGCTGGGCT
CGAGCACCACCACCACCACCACTGA 
 
 
Supplemental Table 13. Amino acid sequences of reported biocatalysts. These sequences are 
also available as a supplemental csv file. 
Protein Amino acid sequence 
ApePgb 
WT 
MTPSDIPGYDYGRVEKSPITDLEFDLLKKTVMLGEKDVMYLKKACDVLKDQVDEILDLWYGWVASNE
HLIYYFSNPDTGEPIKEYLERVRARFGAWILDTTCRDYNREWLDYQYEVGLRHHRSKKGVTDGVRTV
PHIPLRYLIAFIYPITATIKPFLAKKGGSPEDIEGMYNAWFKSVVLQVAIWSHPYTKENDWLEHHHH
HH* 
ApePgb 
Y60G 
MTPSDIPGYDYGRVEKSPITDLEFDLLKKTVMLGEKDVMYLKKACDVLKDQVDEILDLWGGWVASNE
HLIYYFSNPDTGEPIKEYLERVRARFGAWILDTTCRDYNREWLDYQYEVGLRHHRSKKGVTDGVRTV
PHIPLRYLIAFIYPITATIKPFLAKKGGSPEDIEGMYNAWFKSVVLQVAIWSHPYTKENDWLEHHHH
HH* 
ApePgb 
W59A 
Y60G 
MTPSDIPGYDYGRVEKSPITDLEFDLLKKTVMLGEKDVMYLKKACDVLKDQVDEILDLAGGWVASNE
HLIYYFSNPDTGEPIKEYLERVRARFGAWILDTTCRDYNREWLDYQYEVGLRHHRSKKGVTDGVRTV
PHIPLRYLIAFIYPITATIKPFLAKKGGSPEDIEGMYNAWFKSVVLQVAIWSHPYTKENDWLEHHHH
HH* 
ApePgb 
W59A 
Y60G 
F145W 
("AGW") 
MTPSDIPGYDYGRVEKSPITDLEFDLLKKTVMLGEKDVMYLKKACDVLKDQVDEILDLAGGWVASNE
HLIYYFSNPDTGEPIKEYLERVRARFGAWILDTTCRDYNREWLDYQYEVGLRHHRSKKGVTDGVRTV
PHIPLRYLIAWIYPITATIKPFLAKKGGSPEDIEGMYNAWFKSVVLQVAIWSHPYTKENDWLEHHHH
HH* 
RmaNOD 
WT 
MAPTLSEQTRQLVRASVPALQKHSVAISATMYRLLFERYPETRSLFELPERQIHKLASALLAYARSI
DNPSALQAAIRRMVLSHARAGVQAVHYPLVWECLRDAIKEVLGPDATETLLQAWKEAYDFLAHLLST
KEAQVYAVLAELEHHHHHH* 
RmaNOD 
Q52V 
MAPTLSEQTRQLVRASVPALQKHSVAISATMYRLLFERYPETRSLFELPERVIHKLASALLAYARSI
DNPSALQAAIRRMVLSHARAGVQAVHYPLVWECLRDAIKEVLGPDATETLLQAWKEAYDFLAHLLST
KEAQVYAVLAELEHHHHHH* 
P411-CIS 
MTIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACDESR
FDKNLSQALKFARDFAGDGLVTSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLVQKWERL
NADEHIEVSEDMTRLTLDTIGLCGFNYRFNSFYRDQPHPFIISMVRALDEVMNKLQRANPDDPAYDE
NKRQFQEDIKVMNDLVDKIIADRKARGEQSDDLLTQMLNGKDPETGEPLDDGNIRYQIITFLIAGHE
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ATSGLLSFALYFLVKNPHVLQKVAEEAARVLVDPVPSYKQVKQLKYVGMVLNEALRLWPTAPAFSLY
AKEDTVLGGEYPLEKGDEVMVLIPQLHRDKTVWGDDVEEFRPERFENPSAIPQHAFKPFGNGQRASI
GQQFALHEATLVLGMMLKHFDFEDHTNYELDIKETLTLKPKGFVVKAKSKKIPLGGIPSPSTEQSAK
KVRKKAENAHNTPLLVLYGSNMGTAEGTARDLADIAMSKGFAPQVATLDSHAGNLPREGAVLIVTAS
YNGHPPDNAKQFVDWLDQASADEVKGVRYSVFGCGDKNWATTYQKVPAFIDETLAAKGAENIADRGE
ADASDDFEGTYEEWREHMWSDVAAYFNLDIENSEDNKSTLSLQFVDSAADMPLAKMHGAFSTNVVAS
KELQQPGSARSTRHLEIELPKEASYQEGDHLGVIPRNYEGIVNRVTARFGLDASQQIRLEAEEEKLA
HLPLAKTVSVEELLQYVELQDPVTRTQLRAMAAKTVCPPHKVELEALLEKQAYKEQVLAKRLTMLEL
LEKYPACEMKFSEFIALLPSIRPRYYSISSSPRVDEKQASITVSVVSGEAWSGYGEYKGIASNYLAE
LQEGDTITCFISTPQSEFTLPKDPETPLIMVGPGTGVAPFRGFVQARKQLKEQGQSLGEAHLYFGCR
SPHEDYLYQEELENAQSEGIITLHTAFSRMPNQPKTYVQHVMEQDGKKLIELLDQGAHFYICGDGSQ
MAPAVEATLMKSYADVHQVSEADARLWLQQLEEKGRYAKDVWAGLEHHHHHH* 
P411-UA 
MTIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACDESR
FDKNLSQAYKFARDFAGDGLVTSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLVQKWERL
NADEHIEVSEDMTRLTLDTIGLCGFNYRFNSFYRDQPHPFIISMVRAIDEVMNKLQRANPDDPAYDE
NKRQFQEDIKVMNDLVDKIIADRKARGEQSDDLLTQMLNGKDPETGEPLDDGNIRYQIITFLIAGHE
ATSGLLSFALYFLVKNPHVLQKVAEEAARVLVDPVPSYKQVKQLKYVGMVLNEALRLWPTAPAFSLY
AKEDTVLGGEYPLEKGDEVMVLIPQLHRDKTVWGDDVEEFRPERFENPSAIPQHAFKPFGNGQRASI
GQQFALHEATLVLGMMLKHFDFEDHTNYELDIKETFQLKPKGFVVKAKSKKIPLGGIPSPSTEQSAK
KVRKKAENAHNTPLLVLYGSNMGTAEGTARDLADIAMSKGFAPQVATLDSHAGNLPREGAVLIVTAS
YNGHPPDNAKQFVDWLDQASADEVKGVRYSVFGCGDKNWATTYQKVPAFIDETLAAKGAENIADRGE
ADASDDFEGTYEEWREHMWSDVAAYFNLDIENSEDNKSTLSLQFVDSAADMPLAKMHGAFSTNVVAS
KELQQPGSARSTRHLEIELPKEASYQEGDHLGVIPRNYEGIVNRVTARFGLDASQQIRLEAEEEKLA
HLPLAKTVSVEELLQYVELQDPVTRTQLRAMAAKTVCPPHKVELEALLEKQAYKEQVLAKRLTMLEL
LEKYPACEMKFSEFIALLPSIRPRYYSISSSPRVDEKQASITVSVVSGEAWSGYGEYKGIASNYLAE
LQEGDTITCFISTPQSEFTLPKDPETPLIMVGPGTGVAPFRGFVQARKQLKEQGQSLGEAHLYFGCR
SPHEDYLYQEELENAQSEGIITLHTAFSRMPNQPKTYVQHVMEQDGKKLIELLDQGAHFYICGDGSQ
MAPAVEATLMKSYADVHQVSEADARLWLQQLEEKGRYAKDVWAGLEHHHHHH* 
P411-
UA-V87C 
MTIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACDESR
FDKNLSQAYKFARDFAGDGLCTSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLVQKWERL
NADEHIEVSEDMTRLTLDTIGLCGFNYRFNSFYRDQPHPFIISMVRAIDEVMNKLQRANPDDPAYDE
NKRQFQEDIKVMNDLVDKIIADRKARGEQSDDLLTQMLNGKDPETGEPLDDGNIRYQIITFLIAGHE
ATSGLLSFALYFLVKNPHVLQKVAEEAARVLVDPVPSYKQVKQLKYVGMVLNEALRLWPTAPAFSLY
AKEDTVLGGEYPLEKGDEVMVLIPQLHRDKTVWGDDVEEFRPERFENPSAIPQHAFKPFGNGQRASI
GQQFALHEATLVLGMMLKHFDFEDHTNYELDIKETFQLKPKGFVVKAKSKKIPLGGIPSPSTEQSAK
KVRKKAENAHNTPLLVLYGSNMGTAEGTARDLADIAMSKGFAPQVATLDSHAGNLPREGAVLIVTAS
YNGHPPDNAKQFVDWLDQASADEVKGVRYSVFGCGDKNWATTYQKVPAFIDETLAAKGAENIADRGE
ADASDDFEGTYEEWREHMWSDVAAYFNLDIENSEDNKSTLSLQFVDSAADMPLAKMHGAFSTNVVAS
KELQQPGSARSTRHLEIELPKEASYQEGDHLGVIPRNYEGIVNRVTARFGLDASQQIRLEAEEEKLA
HLPLAKTVSVEELLQYVELQDPVTRTQLRAMAAKTVCPPHKVELEALLEKQAYKEQVLAKRLTMLEL
LEKYPACEMKFSEFIALLPSIRPRYYSISSSPRVDEKQASITVSVVSGEAWSGYGEYKGIASNYLAE
LQEGDTITCFISTPQSEFTLPKDPETPLIMVGPGTGVAPFRGFVQARKQLKEQGQSLGEAHLYFGCR
SPHEDYLYQEELENAQSEGIITLHTAFSRMPNQPKTYVQHVMEQDGKKLIELLDQGAHFYICGDGSQ
MAPAVEATLMKSYADVHQVSEADARLWLQQLEEKGRYAKDVWAGLEHHHHHH* 
P411-
UA-V87F 
MTIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACDESR
FDKNLSQAYKFARDFAGDGLFTSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLVQKWERL
NADEHIEVSEDMTRLTLDTIGLCGFNYRFNSFYRDQPHPFIISMVRAIDEVMNKLQRANPDDPAYDE
NKRQFQEDIKVMNDLVDKIIADRKARGEQSDDLLTQMLNGKDPETGEPLDDGNIRYQIITFLIAGHE
ATSGLLSFALYFLVKNPHVLQKVAEEAARVLVDPVPSYKQVKQLKYVGMVLNEALRLWPTAPAFSLY
AKEDTVLGGEYPLEKGDEVMVLIPQLHRDKTVWGDDVEEFRPERFENPSAIPQHAFKPFGNGQRASI
GQQFALHEATLVLGMMLKHFDFEDHTNYELDIKETFQLKPKGFVVKAKSKKIPLGGIPSPSTEQSAK
KVRKKAENAHNTPLLVLYGSNMGTAEGTARDLADIAMSKGFAPQVATLDSHAGNLPREGAVLIVTAS
YNGHPPDNAKQFVDWLDQASADEVKGVRYSVFGCGDKNWATTYQKVPAFIDETLAAKGAENIADRGE
ADASDDFEGTYEEWREHMWSDVAAYFNLDIENSEDNKSTLSLQFVDSAADMPLAKMHGAFSTNVVAS
KELQQPGSARSTRHLEIELPKEASYQEGDHLGVIPRNYEGIVNRVTARFGLDASQQIRLEAEEEKLA
HLPLAKTVSVEELLQYVELQDPVTRTQLRAMAAKTVCPPHKVELEALLEKQAYKEQVLAKRLTMLEL
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LEKYPACEMKFSEFIALLPSIRPRYYSISSSPRVDEKQASITVSVVSGEAWSGYGEYKGIASNYLAE
LQEGDTITCFISTPQSEFTLPKDPETPLIMVGPGTGVAPFRGFVQARKQLKEQGQSLGEAHLYFGCR
SPHEDYLYQEELENAQSEGIITLHTAFSRMPNQPKTYVQHVMEQDGKKLIELLDQGAHFYICGDGSQ
MAPAVEATLMKSYADVHQVSEADARLWLQQLEEKGRYAKDVWAGLEHHHHHH* 
 
 
NMR characterization of cyclopropane products 
 
Supplemental Figure 28. 1H NMR spectrum of cis-3a (1-octene + EDA). 
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Supplemental Figure 29. 1H NMR spectrum of trans-3a (1-octene + EDA). 
 
 
 
 
 
 
Supplemental Figure 30. 1H NMR spectrum of cis-3b (4-phenyl-1-butene + EDA). 
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Supplemental Figure 31. 13C NMR spectrum of cis-3b (4-phenyl-1-butene + EDA). 
 
 
 
 
Supplemental Figure 32. 1H NMR spectrum of trans-3b (4-phenyl-1-butene + EDA). 
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Supplemental Figure 33. 13C NMR spectrum of trans-3b (4-phenyl-1-butene + EDA). 
 
 
 
 
 
Supplemental Figure 34. 1H NMR spectrum of cis-3c (benzyl acrylate + EDA, enzymatic from 
P411-UA V87C). 
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Supplemental Figure 35. 13C NMR spectrum of cis-3c (benzyl acrylate + EDA, enzymatic from 
P411-UA V87C). 
 
 
 
 
 
 
Supplemental Figure 36. 1H NMR spectrum of trans-3c (benzyl acrylate + EDA, enzymatic 
from P411-UA V87F). 
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Supplemental Figure 37. 13C NMR spectrum of trans-3c (benzyl acrylate + EDA, enzymatic 
from P411-UA V87F). 
 
 
 
 
 
 
Supplemental Figure 38. 1H NMR spectrum of cis-3d (6-bromo-1-hexene + EDA). 
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Supplemental Figure 39. 13C NMR spectrum of cis-3d (6-bromo-1-hexene + EDA). 
 
 
 
 
 
Supplemental Figure 40. 1H NMR spectrum of 3d (6-bromo-1-hexene + EDA) diastereomeric 
mixture (~71:29 trans:cis). 
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Supplemental Figure 41. 13C NMR spectrum of 3d (6-bromo-1-hexene + EDA) diastereomeric 
mixture (~71:29 trans:cis). 
 
 
Supplemental Figure 42. 1H NMR spectrum of cis-3e (vinylcyclohexane + EDA).  
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Supplemental Figure 43. 13C NMR spectrum of cis-3e (vinylcyclohexane + EDA). 
 
 
 
 
 
 
 
Supplemental Figure 44. 1H NMR spectrum of 3f (methylenecyclohexane + EDA, enzymatic 
from ApePgb AGW). 
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Supplemental Figure 45. 13C NMR spectrum of 3f (methylenecyclohexane + EDA, enzymatic 
from ApePgb AGW). 
 
 
 
 
 
 
Supplemental Figure 46. 1H NMR spectrum of trans-3g (1-penten-3-one + EDA). 
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Supplemental Figure 47. 13C NMR spectrum of trans-3g (1-penten-3-one + EDA). 
 
 
 
 
 
Supplemental Figure 48. 1H NMR spectrum of cis-3g (1-penten-3-one + EDA). 
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Supplemental Figure 49. 13C NMR spectrum of cis-3g (1-penten-3-one + EDA). 
 
 
 
 
Supplemental Figure 50. 1H NMR spectrum of trans-3h (2-vinylpyridine + EDA). 
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Supplemental Figure 51. 13C NMR spectrum of trans-3h (2-vinylpyridine + EDA). 
 
 
 
 
 
Supplemental Figure 52. 1H NMR spectrum of cis-3h (2-vinylpyridine + EDA). 
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Supplemental Figure 53. 13C NMR spectrum of cis-3h (2-vinylpyridine + EDA). 
 
 
 
 
 
Supplemental Figure 54. 1H NMR spectrum of cis-3i (7-octen-1-ol + EDA, enzymatic from 
ApePgb AGW). 
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Supplemental Figure 55. 13C NMR spectrum of cis-3i (7-octen-1-ol + EDA, enzymatic from 
ApePgb AGW). 
 
 
 
 
Supplemental Figure 56. 1H NMR spectrum of cis-3ia (para-NO2-benzoyl protected 3i). 
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Supplemental Figure 57. 13C NMR spectrum of cis-3ia (para-NO2-benzoyl protected 3i).  
 
 
 
 
 
Supplemental Figure 58. 1H NMR spectrum of 3j (7-octen-1-oic acid + EDA, enzymatic from 
ApePgb AGW). The carboxylic acid proton at 11.0 ppm is broad and not visible unless the 
spectrum is magnified.  
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Supplemental Figure 59. 13C NMR spectrum of 3j (7-octen-1-oic acid + EDA, enzymatic from 
ApePgb AGW). 
 
 
 
 
 
Supplemental Figure 60. 1H NMR spectrum of cis-3ja (benzyl-protected 3j). 
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Supplemental Figure 61. 13C NMR spectrum of cis-3ja (benzyl protected 3j). 
 
 
 
 
 
 
 
Supplemental Figure 62. 1H NMR spectrum of trans-3ja (benzyl-protected 3j). 
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Supplemental Figure 63. 13C NMR spectrum of trans-3ja (benzyl protected 3j). 
 
 
 
 
 
 
Supplemental Figure 64. 1H NMR spectrum of cis-3k ((E)-penta-1,3-diene + EDA, enzymatic 
from ApePgb AGW). 
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Supplemental Figure 65. 1H NMR spectrum of trans-3k ((E)-penta-1,3-diene + EDA, enzymatic 
from RmaNOD Q52V). 
 
 
 
Supplemental Figure 66. 13C NMR spectrum of trans-3k ((E)-penta-1,3-diene + EDA, 
enzymatic from RmaNOD Q52V). 
 71 
 
 
Supplemental Figure 67. 1H NMR spectrum of cis-3l ((Z)-penta-1,3-diene + EDA, enzymatic 
from ApePgb AGW). 
 
 
 
Supplemental Figure 68. 13C NMR spectrum of cis-3l ((Z)-penta-1,3-diene + EDA, enzymatic 
from ApePgb AGW). 
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Supplemental Figure 69. 1H NMR spectrum of cis-3m (5-hexen-2-one + EDA, enzymatic from 
ApePgb AGW). 
 
 
 
Supplemental Figure 70. 13C NMR spectrum of cis-3m (5-hexen-2-one + EDA, enzymatic from 
ApePgb AGW). 
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